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ABSTRACT

Author: Marks, Isaac, J. PhD
Institution: Purdue University
Degree Received: August 2018
Title: Design, Synthesis, and Biological Evaluation of Small Molecule Drug Conjugates
Targeting the Carbonic Anhydrase IX Receptor And Investigation of a Ligand Targeted
Strategy for Targeted Cell-Based Therapies
Committee Chair: Philip Low

Carbonic anhydrase IX (CAIX) is a membrane-spanning zinc metalloenzyme that catalyzes
the reversible consumption of CO2 and water to form H+ + HCO3- in hypoxic and acidic
environments. Many human cancers upregulate CAIX to help control their pH in hypoxic
microenvironments. The consequent overexpression of CAIX on malignant cells and low
expression on normal tissues renders CAIX a particularly attractive target for small molecule
inhibitors, antibody drug conjugates, and ligand-targeted drugs. In this study, CAIX-targeted
fluorescent reporter molecules were initially exploited to investigate CAIX-specific binding to
multiple cancer cell lines in vitro and were shown to exhibit potent, selective in vitro binding
characteristics. A small molecule CAIX-targeted tubulysin B conjugate was then synthesized and
examined for its ability to kill CAIX-expressing tumor cells in vitro and in vivo. These therapeutic
conjugates were shown to be efficacious in several xenograph models without exhibiting signs of
gross toxicity. Because most solid tumors contain hypoxic regions where CAIX is over-expressed,
development of a method to selectively deliver drugs to these hypoxic regions could aid in the
therapy of otherwise difficult to treat tumors.

1

DEVELOPMENT OF A NOVEL FLUOROBENZOSULFONAMIDE (FBSA) AS A SMALL MOLECULE TARGETING
LIGAND FOR CARBONIC ANYDRASE IX

1.1

Introduction

1.1.1 Pathology of Carbonic Anhydrase IX in Human Diseases
Rapidly growing tumors can outgrow their existing vasculature, resulting in the formation
of hypoxic niches that rely upon anaerobic glycolytic metabolism. While these regions may not
make up a significant portion of the tumor volume,1-3 they play a disproportionately important role
in cancer survival and metastasis. The reliance of cancer cells upon anaerobic glycolytic
metabolism is known as the Warburg effect4 and results in the production of acidic metabolites
such as lactic and carbonic acids which lower the extracellular pH in the tumor microenvironment.
Many types of cancers have adaptive mechanisms to mitigate the harsh conditions of low
extracellular pH and hypoxia. One such mechanism is the expression of the transmembrane zinc
metalloenzyme carbonic anhydrase IX (CAIX) which reversibly catalyzes the hydration of CO2 to
form bicarbonate (CO2 + H2O ↔ HCO3− + H+).5 The transport of bicarbonate into the intracellular
space allows the cell to preserve the slightly alkaline intracellular pH necessary for proliferation,
membrane structural integrity, and metabolism required for cellular homeostasis. The proton
produced by the hydration of CO2 remains in the extracellular space and helps to contribute to the
acidification of the microenvironment of solid neoplasms.6, 7

2
1.1.2 Structure, Function, and Expression Patterns of CAIX
CAIX is a zinc metalloprotein and is a member of the large family of carbonic anhydrase
enzymes of 16 mammalian isoforms. They are expressed in various compartments in the cells
including the plasma membrane (e.g., CAIV, CAIX, CAXII) and the cytoplasm (e.g., CAI, CAII,
CAIII). CAIX is composed of four primary domains: the catalytic domain that features a zinc
molecule complexed with the imidazoles from three histidines, an N-terminal proteoglycan-like
domain, a transmembrane portion, and an intracellular domain.8, 9
As a result of the hypoxia-inducible factor 1a (HIF-1a)-mediated signaling cascade, genes
that regulate epithelial-mesenchymal transition (EMT) are stimulated and transform cancer cells
into a stem cell-like mesenchymal migratory state.10-12 Tumor cells undergoing EMT are
implicated in disease progression, metastasis, and overall poor prognosis.13, 14 Furthermore, these
cells are problematic to treat due their quiescent state that renders anti-mitotic drugs useless. These
cells also exhibit other drug resistance mechanisms including upregulation of multi-drug resistance
pumps,15, 16 enhanced DNA repair,17 and dysregulated apoptotic pathways.18, 19 As a consequence,
many tumors that appear to initially respond to chemotherapeutic drugs exhibit disease relapse
after treatment.20-27 CA IX is particularly attractive as a cancer target because of its upregulation
in hypoxic niches in non-small cell lung cancer,28-31 colorectal,32, 33 pancreas,34, 35 breast,36-38,
cervix,39-42 bladder,43,

44

ovarian,45,

46

brain,47,

48

head & neck,49 and kidney cancers.50-53

Importantly, CAIX expression in healthy tissue is limited to very low levels in the gastric mucosa
of the stomach, duodenum, and gall bladder.54-56

3
1.1.3 Therapeutic and Imaging Interventions Targeting CAIX
The primary method of targeting the CAIX receptor for therapeutic intervention is through
small molecule inhibitors (SMIs). The primary class of SMIs are compounds containing aromatic
sulfonamide and sulfamate functional groups to promote coordination of the zinc at the CAIX
active site and competitively interfering with CAIX’s function. The most popular SMI is the FDAapproved sulfonamide acetazolamide; others include dichlorphenamide,57 ethoxazolamide,58 and
brinzolamide.59 While most of the SMIs are designed to incorporate aromatic sulfurs,60-65 there are
several other interesting approaches that have demonstrated preclinical potential including
modified coumarins,66, 67 phenols, 68 and fullerenes.69
The second method to treat CAIX-positive cancers is an immunotherapeutic approach
using with monoclonal antibodies and anti-CAIX antibody-drug conjugates (ADCs). Selective,
humanized monoclonal anti-CAIX antibodies are particularly attractive because they are relatively
easy to generate and, because they do not cross the plasma membrane, they are unable to bind to
intracellular carbonic anhydrases thereby increasing their inherent selectivity.

70

One such

example is girentuximab, a chimeric IgG1 monoclonal antibody for CAIX in late-stage clinical
development.71 Girentuximab has also been used in ADC radioimaging applications by labeling it
with

124

I for the diagnosis of CAIX-positive neoplasms.72 Therapeutic ADCs are also in clinical

development delivering cytotoxic payloads like monomethyl auristatin E.73
The final approach used to target CAIX is through small molecule drug conjugates
(SMDCs). SMDCs are very similar to ADCs except that the targeting moiety is a small molecule
or peptide instead of a large antibody. CAIX-targeted SMDCs have been designed to carry
fluorescent dyes for fluorescence-guided surgery,74 radioimaging contrast agents like
SPECT/CT imaging75-77 and

68

Ga,

64

Cu, and

18

99m

Tc for

F for PET/CT radioimaging,78-80 and therapeutic

applications carrying antineoplastic payloads including DM181, 82 and tubulysin B83. While these
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approaches have been successful in preclinical studies, there is an unmet need for potent, selective
SMDCs targeting CAIX to deliver imaging and therapeutic cargos specifically to CAIX-positive
cancers.

1.2

Materials and Methods

1.2.1 Chemicals and Materials
H-Cys(Trt)-2-chlorotrityl resin and L-aspartic acid ß-tert-butyl 2-chlorotrityl resins were
obtained from Novabiochem (San Diego, CA). Amino acids were purchased from Chem-Impex
International (Chicago, IL). Tubulysin B hydrazide (TubB) was provided by Endocyte, Inc. (West
Lafayette, IN). HATU was obtained from Genscript Inc. (Piscataway, NJ). Sulfuric acid, methanol,
DMSO, DMF, TFA, IPA, DIPEA, piperidine, CH2Cl2, K2CO3, and all other chemical reagents
were purchased from Sigma Aldrich (St. Louis, MO). Multi-well plates were purchased from BD
Biosciences (San Jose, CA). [3H]-Thymidine was obtained from Moravek Biochemicals (Brea,
CA). All other cell culture reagents, syringes, and disposable items were purchased from VWR
(Chicago, IL).

1.2.2 Confocal Fluorescence Microscopy
Human cells were seeded into chambered glass bottom plates and allowed to grow to
confluence over 24 h. Growth medium was replaced with 0.5 mL of fresh medium containing 10%
fetal bovine serum albumin and 25 nM concentration of the FBSA-FITC conjugate alone or the
dye conjugate plus 100-fold excess of the unmodified FBSA CAIX inhibitor. After incubation for
1 hour at 37 °C, cells were rinsed twice with 1 mL of media to remove any compound that was

5
non-specifically bound and 0.5 mL of fresh growth medium was added to the wells. Images were
acquired using a confocal microscopy (FV 1000, Olympus).

1.2.3 General Procedure for Determination of Binding Affinity of CAIX-FITC Conjugates
Untransfected cells (SKRC52, HT29, A549) or HEK293 cells transfected with CAIX
(0.25 x 106) were placed into 1.5 mL centrifuge tubes with 0.3 mL of fresh DMEM or RPMI
medium containing increasing concentrations of FBSA-FITC conjugates in the presence or
absence of 100-fold excess FBSA inhibitor. All concentrations were examined in duplicate or
triplicate. After incubating for 1 h at 25 °C, cells were rinsed twice with 1 mL of medium. The
cells were transferred into a 96-well plate and the mean florescence intensity (MFI) was read by
flow cytometry (BD Accuri C6, BD Biosciences). Apparent KD was calculated by plotting the
mean fluorescence intensity (MFI) versus the concentration of FITC conjugates using GraphPad
Prism 4 and reported as the mean plus or minus the standard error. For hypoxia experiments, cells
were incubated under an atmosphere containing 1% oxygen, 5% carbon dioxide, and 94% nitrogen
for 24-48 hours in a sealed chamber.
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1.2.4 Synthesis of FBSA Conjugates

1.2.4.1 Synthesis of FBSA Starting Material

3-((2,3,5,6-Tetrafluoro-4-sulfamoylphenyl)sulfonyl)propanoic acid (1.3)84
The sulfonamide 1.2 was synthesized and purified according to published methods.85 1.2
(950.4 mg, 3.8 mmol), triethylamine (1.4 mL, 19 mmol) and 3-mercaptopropanoic acid (0.364
mL,4.2 mmol) were dissolved in methanol (40 mL). The reaction was then heated to reflux and
stirred for 24 hours. Upon completion, and the solvent removed under reduced pressure. The
resulting residue was then dissolved in 50 mL of 2:1 AcOH:H2O. The solution was then heated to
70 °C and 2 mL portions of 30% hydrogen peroxide was added every 2 hours until the total volume
of peroxide added reached 10 mL. The reaction was then allowed to stir at 70 °C for a total of 24
hours. Acetic acid was removed under vacuum, the resulting precipitate was filtered, and the
product was washed with cold water (41% yield). LRMS-LC/MS (m/z): 383.0 [M + H2O].
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3-((2-(Cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)propanoic acid (FBSA, 1.4)

Compound 1.3 (400 mg, 1.1 mmol) and cyclooctylamine (0.3 mL, 2.2 mmol) was stirred
in DMSO (2 mL) at room temperature for 24 hours. The reaction was purified using RP-HPLC [A
= 20 mM ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 100% B in
30 min], yielding 1.3 as a yellow solid (32% yield). LRMS-LC/MS (m/z): 473.2 [M + H]+.
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1.2.4.2 Synthesis of FBSA-FITC Conjugates

(2R,5S,8S)-8-Amino-5-(carboxymethyl)-29-((2-(cyclooctylamino)-3,5,6-trifluoro-4sulfamoylphenyl)sulfonyl)-2-(mercaptomethyl)-4,7,11,27-tetraoxo-14,17,20,23-tetraoxa3,6,10,26-tetrAZManonacosanoic acid (1.5)

Compound 1.5 was synthesized by the following solid phase methodology: H-Cys(Trt)-2chlorotrityl resin (100 mg, 0.64 mmol/g) was bubbled with 3 mL of DCM followed by 3 mL of
DMF. After swelling the resin, a solution of Fmoc-Asp(tBu)-OH (52.7 mg, 0.128 mmol), HATU
(60.8 mg, 0.16 mmol) and DIPEA (0.056 mL, 0.32 mmol) in DMF (3 mL) was added. Argon was
bubbled for 2 h, and resin was washed with DMF (3 x 3 mL) and IPA (3 x 3 mL). The Fmoc was
removed with a piperidine solution (20% in DMF, 3x5 mL) and the resin was washed with DMF
(3 x 3 mL) and IPA (3 x 3 mL). A solution of Boc-DAP(Fmoc)-OH (54.6 mg, 0.128 mmol), HATU
(60.8 mg, 0.16 mmol) and DIPEA (0.056 mL, 0.32 mmol) in DMF (3 mL) was added. Argon was
bubbled for 2 h, and resin was washed with DMF (3 x 3 mL) and IPA (3 x 3 mL). The Fmoc was
removed with a piperidine solution (20% in DMF, 3 x 5 mL) and the resin was washed with DMF
(3 x 3 mL) and IPA (3 x 3 mL). A solution of Fmoc-15-amino-4,7,10,13-tetraoxapentadecanoic
acid (62.4 mg, 0.128 mmol), HATU (60.8 mg, 0.16 mmol) and DIPEA (0.056 mL, 0.32 mmol) in
DMF was added. Argon was bubbled for 2 h, and resin was washed with DMF (3 x 3 mL) and
DCM (3 x 3 mL). The Fmoc was removed with a piperidine solution (20% in DMF, 3X 5 mL) and
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the resin was washed with DMF (3 x 3 mL) and IPA (3 x 3 mL). A solution of FBSA-COOH
(1.4, 33.3mg, 0.074 mmol), HATU (24.3 mg, 0.064 mmol) and DIPEA (0.034 mL, 0.192 mmol)
in DMF was added. Argon was bubbled for 2 h, and resin was washed with DMF (3 x 3 mL) and
DCM (3 x 3 mL). Compound 1.4 was cleaved from the resin using a TFA:TIPS:H2O:EDT cocktail
(95:2.5:2.5:2.5) and concentrated under vacuum. The concentrated product was precipitated in
diethyl ether and dried under vacuum. Crude conjugate was purified by RP-HPLC [A = 20 mM
ammonium acetate buffer (pH 5.0), B = CH3CN, solvent gradient: 0% B to 100% B in 30 min] to
yield the product as a clear oil (62% yield). LRMS-LC/MS (m/z): 1024.3 [M + H]+.

5-(3-(((2R,5S,8S)-8-amino-2-carboxy-5-(carboxymethyl)-29-((2-(cyclooctylamino)-3,5,6trifluoro-4-sulfamoylphenyl)sulfonyl)-4,7,11,27-tetraoxo-14,17,20,23-tetraoxa-3,6,10,26tetrAZManonacosyl)thio)-2,5-dioxopyrrolidin-1-yl)-2-(6-hydroxy-3-oxo-3H-xanthen-9yl)benzoic acid (1.6)
To a solution of 1.5 (2 mg, 0.002 mmol) in DMF (1 mL) was added fluorescein-5maleimide (0.85 mg, 0.002 mmol) and DIPEA (0.002 mL, 0.01 mmol) and stirred for 1 hour at
room temperature. The crude reaction mixture was purified using RP-HPLC [A = 2 mM
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ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 100% B in 30 min] to
yield the product as a yellow powder (76% yeild). LRMS-LC/MS (m/z): 1451.3 [M + H]+.

Tert-butyl (2-(3-((2-(cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)
propanamido)ethyl)carbamate (1.7)
To a solution of 3-((2-(cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)
propanoic acid (20 mg, 0.042 mmol) in DMF (2 mL) was added tert-butyl (2aminoethyl)carbamate (7.40 mg, 0.0462 mmol) and allowed to stir under argon for 10 minutes at
room temperature. HATU (16 mg, 0.042 mmol) and DIPEA (0.022 mL, 0.126 mmol) were then
added. The reaction was stirred for 1 hour before quenching with water (10 mL) and extracted with
ethyl acetate (3 x 25 mL). The organic layers were combined, washed with brine, and dried over
anhydrous sodium sulfate. The solvent was concentrated under vacuum, and the crude mixture was
purified on silica gel using 10% methanol/dichloromethane to obtain 1.7 as a colorless oil (83%
yield). LRMS-LC/MS (m/z): 615.2 [M + H]+.
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5-(3-(2-(3-((2-(Cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)
propanamido)ethyl)thioureido)-2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)benzoic acid (1.8)
The tert-butyloxycarbonyl protecting group of compound 1.7 (10 mg, 0.008 mmol) was
removed with a mixture of TFA/DCM (20%, 2 mL) for 30 minutes. The TFA/DCM mixture was
removed under vacuum and the product brought forward without purification. To the vial
containing the deprotected 13, was added DMF (1 mL) and DIPEA (0.007 mL, 0.04 mmol) and
allowed to stir for 5 minutes before fluorescein-5-maleimide (3.8 mg, 0.0088 mmol) was added
and allowed to stir for an additional hour. The crude mixture was purified without workup by
purified RP-HPLC [A = 2 mM ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient:
0% B to 100% B in 30 min] to yield 1.8 as a yellow powder (76% yield). LRMS-LC/MS (m/z):
904.2 [M + H]+.
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(3-(2-(2-(3-((2-(Cyclooctylamino)-3,5,6-trifluoro-4sulfamoylphenyl)sulfonyl)propanamido)ethoxy)ethoxy)propanoyl)cysteine (1.9)
Compound 1.9 was synthesized by the following solid phase methodology. H-Cys(Trt)-2chlorotrityl resin (100 mg, 0.64 mmol/g) was swollen with 3 mL of DCM followed by 3 mL of
DMF. A solution of 3-[2-[2-(9H-fluoren-9-ylmethoxycarbonylamino)ethoxy]ethoxy]propanoic
acid (51.1 mg, 0.128 mmol), HATU (60.8 mg, 0.16 mmol) and DIPEA (0.056 mL, 0.32 mmol) in
DMF (3 mL) was added. Argon was bubbled for 2 h, and resin was washed three times with 3 mL
of DMF and 3 times with 3 mL IPA. The Fmoc was removed with a piperidine solution (20% in
DMF, 3 x 5 mL) and the resin was washed with DMF (3 x 3 mL) and DCM (3 x 3 mL). A solution
of 3-((2-(cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)propanoic acid (33.3mg,
0.074 mmol), HATU (24.3 mg, 0.064 mmol) and DIPEA (0.034 mL, 0.192 mmol) in DMF was
added. Argon was bubbled for 2 h, and resin was washed three times with DMF (3 x 3 mL) and
DCM (3 x 3 mL). Compound 1.9 was cleaved from the resin using a TFA:TIPS:H2O:EDT cocktail
(95:2.5:2.5:2.5) and concentrated under vacuum. The concentrated product was precipitated in
diethyl ether and dried under vacuum. Crude conjugate was purified by reverse-phase HPLC [A
= 2 mM ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 100% B in 30
min] to yield the product as a clear oil (54% yield). LRMS-LC/MS (m/z): 735.2 [M + H]+.
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2-(((1-(3-Carboxy-4-(6-hydroxy-3-oxo-3H-xanthen-9-yl)phenyl)-2,5-dioxopyrrolidin-3yl)thio)methyl)-16-((2-(cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)-4,14-dioxo7,10-dioxa-3,13-diazahexadecanoic acid (1.10)
To a solution of 1.9 (5 mg, 0.0068 mmol) in DMF (1 mL) was added fluorescein-5maleimide (3.2 mg, 0.0075 mmol) and DIPEA (0.006 mL, 0.034 mmol) and stirred for 1 hour at
room temperature. The crude reaction mixture was purified reverse-phase HPLC [A = 2 mM
ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 100% B in 30 min] to
yield the product as a yellow powder (61% yield). LRMS-LC/MS (m/z): 1162.2 [M + H]+.

1.3

Results and Discussion

1.3.1 Design of FBSA-Based SMDCs for Carbonic Anhydrase IX Expressing Cancers
Because the established CAIX-targeting ligands that have been previously reported have
exhibited only moderate binding affinity (25-50 nM) and specificity for CAIX,74 there is an unmet
need to generate SMDCs with increased potency and selectivity. To accomplish that goal, the
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CAIX small molecule inhibitor shown in Figure 1.1 was selected for use as the targeting moiety
for a novel CAIX SMDC.

Figure 1.1 Redesign of FBSA for Use as a Targeting Ligand

The fluoro-benzosulfonamide (FBSA) small molecule inhibitor was developed by
Dudutiene and coworkers86 and exhibits high specificity (66-fold over the closely related CAXII)
and potency (Ki = 50 pM) for CAIX. As shown in Figure 1.1, a modified version of the inhibitor
was synthesized for ease of attachment to the flexible linker, featuring a carboxylic acid functional
group to replace the alkyl alcohol. The carboxylic acid functionality makes 1.4 amenable to amide
bond formation with any linker that contains a free amine in addition to making it compatible with
the solid-phase peptide synthetic strategies employed to synthesize several of the FBSA-based
SMDCs described below.
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Scheme 1.1 Synthesis of FBSA-COOH, 1.4, a CAIX inhibitor with carboxylic acid functionality

All ligand-targeted drug conjugates are composed of three components: the targeting
moiety (small molecules, peptides, proteins, etc.) for the receptor of interest, a linker or spacer,
and the cargo. A central concern to the design of SMDCs is to ensure that the spacer is sufficiently
long enough to allow for the cargo to avoid steric interactions with the receptor that might reduce
the binding affinity and efficacy of the conjugate. Every receptor will be different: some proteins
have deep active sites with a long tunnel required to reach it; others will have shallow binding sites
on the surface of the protein that don’t require a long spacer to reach the bottom of the binding
pocket. For example, SMDCs targeting the folate receptor only require an ethylene diamine spacer
attached to the glutamic acid to allow for sufficient clearance for a wide variety of therapeutic and
imaging cargos.87, 88
One way to determine the length of the linker needed to enable the targeting ligand to reach
the bottom of its binding pocket is to examine the crystal structure of the receptor, if it has been
solved. In the case of CAIX, several protein structures are available, and a suitable one was
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selected for this purpose (PDB code: 4Q07).86 As shown in Figure 1.2, the measurement of the
binding pocket showed that a linker of about 20 Å would be required for optimal binding of the
targeting ligand to the Zn at the bottom on the binding site. It is worthwhile to note that the conical
shape of binding pocket may assist with the accommodation of large SMDC cargos.

Figure 1.2 Measurement of the CAIX Binding Pocket Depth

To confirm this assessment, several FBSA-FITC conjugates with spacers of different
lengths were synthesized. Schemes 1.2 and 1.4 show the similar solid-phase peptide synthetic
approaches to the syntheses of FBSA-PEG4-FITC (compound 1.6) and FBSA-PEG2-FITC
(compound 1.10). A solution-phase synthetic approach was used for the synthesis of the shortest
FBSA-FITC conjugate containing an ethylene diamine (ED) linker (compound 1.8) as shown in
Scheme 1.3. The success of these alternative synthetic approaches serve to demonstrate that the
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FBSA CAIX targeting molecule, modified with a carboxylic acid moiety, is amenable to both
traditional organic synthesis solution phase strategies as well as the relatively harsh conditions
required for solid-phase peptide synthesis.

Scheme 1.2 Synthesis of FBSA-PEG4-FITC (1.6)
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Scheme 1.3 Synthesis of FBSA-EDA-FITC (1.8)

19

Scheme 1.4 Synthesis of FBSA-PEG2-FITC (1.10)

1.3.2 In Vitro Evaluation of 1.10 with Confocal Microscopy
Confocal microscopy is a powerful tool to quickly characterize the in vitro binding
characteristics of SMDCs bearing a fluorescent cargo. There are several key parts of information
that are of interest in this experiment. The potency of the binding of the SMDC to the cells can
determined by incubating the SMDC at varying concentrations; ideally, the SMDC will bind to
the target cells at a concentration of less than 50 nM. Additionally, the specificity of the compound
can be determined using receptor negative cell lines and competition experiments. Competition
experiments are conducted by pre-incubating the target cells with the unlabeled targeting ligand
(with or without the linker) usually in 100-fold excess concentrations followed by incubation of
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the labeled compound in conjunction with the 100-fold excess of un-labeled compound. This is
done to saturate all of the available binding sites on the cell surface and ensure that the labeled
compound does not exhibit non-specific binding to the cell surface. The third piece of information
provided by confocal microscopy is whether or not the SMDC is being internalized to the
intracellular compartments through receptor-mediated endocytosis.
To obtain an initial indication of which human cancer cell lines might upregulate CAIX,
various cell lines were incubated [SKRC-52 (human renal cell carcinoma), HT29 (human colon
adenocarcinoma), A549 (human lung carcinoma) cells, HEK293 (human embryonic kidney) cells
that were transfected with CAIX (positive control)] with 25 nM of the FITC-labeled compound
1.10 and then examined the cells by confocal microscopy. As shown in the representative data of
Figure 1.3, compound 1.10 labeled the surface of the SKRC-52 cells brightly (panel A) in a manner
that was readily competed by addition of 100-fold excess of unlabeled CAIX targeting ligand
(panel B). Similar data were also found for HT-29, A549 and the transfected HEK293 cells,
demonstrating that all four of the examined cell lines express CAIX receptors. Minimal
internalization was observed during the confocal microscopy experiments. While this would not
affect the efficacy of SMDCs for imaging applications, the lack of internalization has the potential
to have an effect upon the efficacy of therapeutic SMDCs that deliver a cargo with a mechanism
of action that solely functions intracellularly and will be discussed further in Chapter 2.
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Figure 1.3 In Vitro Evaluation of FBSA-PEG2-FITC in SKRC52 Cells
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1.3.1 Measurement of the Binding Affinity of 1.10 with Flow Cytometry
While confocal microscopy can quickly provide qualitative data pertaining to the in vitro
efficacy of novel SMDC’s, analysis of the binding characteristics by flow cytometry provides a
much more quantitative output. Each of the aforementioned cell lines were examined with flow
cytometry by incubating them with increasing concentrations of compound 1.10 and analyzed for
mean fluorescence intensity (MFI). As shown in Figure 1.4 and Figure 1.5, analysis of the MFI
yields a binding affinity of ~5 nM for both HT-29 and A549 cells (which was similar to the KD for
SKRC-52 as shown in Figure 1.3), suggesting that attachment of fluorescein to FBSA has only
minor effect on its affinity for CAIX. The fact that the MFI was shifted to near background levels
upon addition of excess unlabeled FBSA further establishes that virtually all of compound 1.10’s
binding is CAIX specific. These data therefore served as evidence that a FBSA-linked drug can
be targeted to CAIX-expressing cancer cells with high affinity and specificity.
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Figure 1.4 In Vitro Binding Affinity of 1.10 in HT29 Cells
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Figure 1.5 In Vitro Binding Affinity of Compound 1.10 in A549 Cells

25
1.3.2. Investigation of the Optimal Linker Length of FBSA-Based SMDCs
The previous in silico examination of the CAIX binding pocket depth showed that the
optimal linker length was about 20 Å as shown in Figure 1.2. In order to experimentally determine
the best linker length, a series of three FBSA-FITC conjugates were synthesized. First, compound
1.8 contained the shortest linker composed of an ethylene diamine linker and the linker length was
approximately 5 Å. The medium length linker was in compound 1.10 with a PEG2 linker with a
length of approximately 20 Å. Compound 1.6 was the conjugate with the longest linker (PEG4
linker) of approximately 40 Å.
The binding affinities of the FBSA-FITC conjugates were then determined using flow
cytometry in several cell lines. First, Figure 1.6 displays the flow data from the SKRC52 cell line,
showing that binding affinity for the medium length linker (compound 1.10) is the best at 1.28 nM.
However, the data from compound 1.6 at 4.57 nM shows conjugates with a longer linker will
exhibit only 3.6-fold less binding affinity than the compound 1.6. As predicted, compound 1.8 had
a 32-fold decrease in the binding affinity, suggesting that there is steric interference between the
hydrophobic cargo (FITC) and the receptor site that affect the efficacy of this SMDC. Additionally
this data was also shown to be true for a second cell line (HEK-CAIX) as shown in Figure 1.7.
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Table 1.1 The Effects of Linker Length upon the Binding Affinity of FBSA-FITC Conjugates in
Human Cancer Cell Lines
Linker

Linker Length
(Å)

Binding
Affinity in
SKRC52 (nM)

Binding Affinity in
HEK293-CAIX (nM)

1.10

PEG2

20

1.28

17.94

1.6

PEG4

40

4.57

55.2

1.8

Ethylene
diamine
(EDA)

5

40.89

215.7

M e a n F lu o r e s c e n c e I n te n s ity ( M F I )

Compound
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Figure 1.6 Binding Affinity of CAIX-FITC conjugates in SKRC52 cells
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Figure 1.7 Binding Affinity of CAIX FITC Conjugates in HEK293-CAIX Cells

1.4

Conclusion
The primary objective of the studies outline in this chapter was to evaluate whether the

FBSA molecule can function as a targeting ligand for a series of novel small molecule drug
conjugates. Repurposing molecules designed as small molecule or peptide modulators of protein
function is an attractive and popular strategy to generate novel ligand-targeting technologies
primarily because the work required to generate these inhibitors can be prohibitively arduous and
expensive.
However, there are several considerations that can limit the utility of these small molecule
inhibitors (SMIs). First, SMIs are often designed to limit the use of reactive chemical
functionalities to avoid offsite reactivity that may result in toxicity. For example, functional groups
amendable for linker ligation (e.g., primary amines, carboxylic acids, unprotected thiols) are often
protected using strategies to mask their reactivity (e.g., using an ester instead of a free carboxylic
acid or using a secondary amine instead of a primary amine). This maintains the ability of these
functional groups to make positive binding interactions with the receptor site but renders them less
reactive. For the repurposing of SMIs as SMDC targeting ligands, it will often require the rational
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substitution of an alternative isostere that is more amenable for linker attachment. In this study,
the FBSA was designed as a SMI with an alkyl alcohol, which could have been used to form an
ester bond with a carboxylic acid-containing linker or an ether with a linker containing an alkyl
halide. However, the substitution of a carboxylic acid for the alkyl alcohol was performed to allow
for the synthetic ease using solid-phase peptide synthetic approaches.
The second important consideration for the repurposing of SMIs for the use as SMDC
targeting moieties is the point of attachment for the linker. If the linker is attached to the SMI in
the wrong location on the molecule, it may interfere with the ability of the SMI to dock into the
binding pocket in the manner in which it was designed. If there is a crystal structure with the SMI
co-crystalized into the protein’s receptor, it provides a known orientation of the SMI and the
attachment of the linker can be made onto the SMI towards the solvent exposed surface of the
target protein. If the crystal structure is not known, the published literature can be examined for
structure-activity relationship (SAR) studies that may review the degree to which certain areas of
the binding pocket are amendable for attachment of additional functionalities. For example, if an
aminomethyl group was on the original molecule but the SAR studies showed that an aminopropyl
group substituted in the same location lost 1000-fold activity when tested for biological activity,
is a good indication that the amino group is orientated towards the inside of the pocket and cannot
be used to form a bond with linker in an SMDC.
The crystal structure was available for CAIX, and the docking pose of FBSA showed that
there was an approximately 20 Å long tunnel leading to the active site of the receptor. After
successfully performing the synthesis of the FBSA-COOH molecule, a series of FBSA-FITC
molecules were synthesized to verify the hypothesis that the linker must be approximately 20 Å or
longer to ensure that there would be minimal steric interference with the large SMDC cargos and
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the CAIX protein surface. After performing a series of flow cytometry experiments with the
FBSA-FITC conjugates, this hypothesis was verified. An additional benefit of the FBSA-FITC
conjugates is that it was exceedingly useful to screen human cell lines for CAIX expression without
needing to rely upon expensive CAIX monoclonal antibodies. In fact, the A549 cell line (human
lung carcinoma) was discovered as expressing very high levels of CAIX; because the other
commonly-used CAIX tumor cell line (SKRC52) requires an extended time to grow tumor in
subcutaneous models (2-3 months), the use of a more rapidly dividing CAIX cell line was would
turn out to be very useful for the therapeutic studies reported in Chapter 2.
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DEVELOPMENT OF THERAPEUTIC FBSA
CONJUGATES

2.1

Introduction
Conventional chemotherapies are infamous for their side effects including nausea, hair loss,

fatigue, organ damage, weight loss, peripheral neuropathy, anemia.89, 90 Classic chemotherapies
are generally non-selective and instead rely upon the higher efficacy of the compounds in rapidly
dividing cells of neoplasms which grants a therapeutic window relative to normal tissues.91
However, some healthy cells also undergo rapid proliferation including in the hair follicles,
digestive tract, and bone marrow are also affected by antineoplastic agents, causing the dose
limiting toxicities. There are many examples of conventional chemotherapies that are still used
today despite their side effects including cisplatin, methotrexate, fluorouracil, and paclitaxel.
Aided by the development of techniques of modern biology, contemporary chemotherapy
drugs are designed using principles of structure-based design to maximize selectivity to avoid offsite toxicities. A prominent example of the success of this approach is imatinib, a small molecule
inhibitor designed as a competitive inhibitor for the Bcr-Abl fusion tyrosine kinase protein found
in chronic myelogenous leukemia (CML).92 Imatinib showed remarkable success in the clinic and
most patients showed complete remission with limited sided effects.
The receptor-mediated delivery of chemotherapy agents has also shown remarkable
success as well. To date, only antibody-targeted conjugates have gained FDA approval for clinical
use to delivery antineoplastic agents. For example, inotuzumab ozogamicin is an FDA-approved
antibody-ozogamicin conjugate targeting CD22 and is indicated for the treatment of acute
lymphoblastic leukemia (ALL).93 Another example of a successful ADC is trastuzumab emtansine
which is composed of the cytotoxic agent emtansine (DM1) targeted to the HER2/neu receptor by
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a monoclonal antibody trastuzumab (Herceptin).94 There are also numerous examples of receptormediated delivery of cytotoxic compounds using small molecules but they have not yet gained
FDA approval. Some prominent examples are EC1456 (folate targeted tubulysin B)95 and EC1169
(PSMA-targeted tubulysin B),96 which are under development by Endocyte, Inc. (West Lafayette,
IN).In this chapter, the design, synthesis, and biological evaluation of FBSA-based CAIX-targeted
microtubule inhibitor is demonstrated. The selective delivery of tubulysin B hydrazide using
FBSA-targeting for multiple CAIX-expressing solid tumors leads to rapid cancer cell death and
tumor shrinkage.

2.2

Materials and Methods

2.2.1 Chemicals and Materials
H-Cys(Trt)-2-chlorotrityl resin and L-aspartic acid ß-tert-butyl 2-chlorotrityl resins were
obtained from Novabiochem (San Diego, CA). Amino acids were purchased from Chem-Impex
International (Chicago, IL). Tubulysin B hydrazide (TubB) was provided by Endocyte, Inc. (West
Lafayette, IN). HATU was obtained from Genscript Inc. (Piscataway, NJ). Sulfuric acid, methanol,
DMSO, DMF, TFA, IPA, DIPEA, piperidine, CH2Cl2, K2CO3, and all other chemical reagents
were purchased from Sigma Aldrich (St. Louis, MO). Multi-well plates were purchased from BD
Biosciences (San Jose, CA). [3H]-Thymidine was obtained from Moravek Biochemicals (Brea,
CA). All other cell culture reagents, syringes, and disposable items were purchased from VWR
(Chicago, IL).
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2.2.2 Synthesis of FBSA Therapeutic Conjugates

2.2.2.1 Synthesis of a FBSA-PEG2-Tubulysin B Conjugate

(2R,5S,8S)-8-Amino-5-(carboxymethyl)-23-((2-(cyclooctylamino)-3,5,6-trifluoro-4sulfamoylphenyl)sulfonyl)-2-(mercaptomethyl)-4,7,11,21-tetraoxo-14,17-dioxa-3,6,10,20tetrAZMatricosanoic acid, 2.1.

Compound 2.1 was synthesized by the following solid phase methodology: H-Cys(Trt)-2chlorotrityl resin (100 mg, 0.64 mmole/g) was swollen with 3 mL of DCM followed by 3 mL of
DMF. After swelling the resin, a solution of Fmoc-Asp(tBu)-OH (52.7 mg, 0.128 mmol), HATU
(60.8 mg, 0.16 mmol) and DIPEA (0.056 mL, 0.32 mmol) in DMF (3 mL) was added. Argon was
bubbled for 2 h, and resin was washed (3 x 3 mL) with DMF and IPA (3 x 3 mL). The Fmoc was
removed with a piperidine solution (20% in DMF, 3 x 5 mL) and the resin was washed with DMF
(3 x 3 mL) and IPA (3 x 3 mL). A solution of Boc-DAP(Fmoc)-OH (54.6 mg, 0.128 mmol),
HATU (60.8 mg, 0.16 mmol) and DIPEA (0.056 mL, 0.32 mmol) in DMF (3 mL) was added.
Argon was bubbled for 2 h, and resin was washed with DMF (3 x 3 mL) and IPA (3 x 3 mL). The
Fmoc was removed with a piperidine solution (20% in DMF, 3 x 5 mL) and the resin was washed
with DMF (3 x 3 mL) and IPA (3 x 3 mL). A solution of Fmoc-9-amino-4,7-dioxanonanoic acid
(51.12 mg, 0.128 mmol), HATU (60.8 mg, 0.16 mmol) and DIPEA (0.056 mL, 0.32 mmol) in
DMF was added. Argon was bubbled for 2 h, and resin was washed with DMF (3 x 3 mL) and IPA
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(3 x 3 mL). The Fmoc was removed with a piperidine solution (20% in DMF, 3X 5 mL) and the
resin was washed with DMF (3 x 3 mL) and IPA (3 x 3 mL). A solution of 3-((2(cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)propanoic acid (compound 1.4,
33.3mg, 0.074 mmol), HATU (24.3 mg, 0.064 mmol) and DIPEA (0.034 mL, 0.192 mmol) in
DMF was added. Argon was bubbled for 2 h, and resin was washed with DMF (3 x 3 mL) and
IPA (3 x 3 mL). Compound 2.1 was cleaved from the resin using a TFA:TIPS:H2O:EDT cocktail
(95:2.5:2.5:2.5) and concentrated under vacuum. The concentrated product was precipitated in
diethyl ether and dried under vacuum. Crude conjugate was purified by RP-HPLC [A = 20 mM
ammonium acetate buffer (pH 5.0), B = CH3CN, solvent gradient: 0% B to 100% B in 30 min,
retention time: 15.6 min] to yield the product as a clear oil (62% yield). LRMS-LC/MS (m/z):
935.2 [M + H]+.
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(3R,5S,16R,19S)-1-(2-((1R,3R)-1-Acetoxy-3-((2S,3S)-N-((butyryloxy)methyl)-3-methyl-2-(1methylpiperidine-2-carboxamido)pentanamido)-4-methylpentyl)thiazol-4-yl)-19-((S)-16-amino1-((2-(cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)-3,13-dioxo-7,10-dioxa-4,14diazaheptadecan-17-amido)-16-carboxy-3-(4-hydroxybenzyl)-5-methyl-1,6,9,18-tetraoxo-10oxa-13,14-dithia-2,7,8,17-tetrAZMahenicosan-21-oic acid, 2.3.

A solution of saturated sodium bicarbonate (10 mL) in distilled water was bubbled with
argon continuously for 30 min. Compound 2.1 (1.5 mg, 0.0016 mmol) was dissolved in argonpurged HPLC grade water (2.0 mL) and the pH of the reaction mixture was increased to 7 using
argon-purged sodium bicarbonate. A solution of activated Tubulysin B, supplied by Endocyte,
Inc. (compound 2.2, 1.86 mg, 0.018 mmol) in THF (0.5 mL) was then added to the reaction mixture.
The progress of the reaction was monitored using analytical LCMS, and after stirring for 30 min,
the reaction was found to reach completion. Compound 2.3 was purified by RP-HPLC [A = 20
mM ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 100% B in 30 min,
retention time: 22.2 min] to yield the requisite product. LRMS-LC/MS (m/z): 1881.5 [M + H]+.
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2.2.2.2 Synthesis of a Hydrophilic FBSA-Tubulysin B Conjugate

(2R,5S,8S,12S,15S,18S)-8-Amino-5,12-bis(carboxymethyl)-18-(3-(2-(2-(3-((2-(cyclooctylamino)3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)propanamido)ethoxy) ethoxy)propanamido)-15-(3guanidinopropyl)-2-(mercaptomethyl)-4,7,11,14,17-pentaoxo-3,6,10,13,16pentAZMaicosanedioic acid, 2.5.

H-Cys(Trt)-2-chlorotrityl resin (2.4, 100 mg, 0.64 mmol/g) was swollen with DCM (3 mL)
for 20 min followed by DMF (3 mL) for 20 min. After swelling the resin, a solution of
Fmoc-Asp(tBu)-OH (52.7 mg, 0.128 mmol), HATU (60.8 mg, 0.16 mmol) and DIPEA (0.056 mL,
0.32 mmol) in DMF (3 mL) was added. Argon was bubbled for 2 h, and resin was washed with
DMF (3 x 3 mL) and IPA (3 x 3 mL). The Fmoc was removed with a piperidine solution (20% in
DMF, 3 x 5 mL) and the resin was washed with DMF (3 x 3 mL) and IPA (3 x 3 mL). The same
protocol was followed for the remaining steps. Compound 2.5 was cleaved from the resin using a
TFA:TIPS:H2O:EDT cocktail (95:2.5:2.5:2.5) and concentrated under vacuum. The concentrated
product was precipitated in diethyl ether and dried under vacuum. Crude conjugate was purified
by RP-HPLC [A = 2 mM ammonium acetate buffer (pH 5.0), B = CH3CN, solvent gradient: 0%
B to 100% B in 30 min, retention time: 19.7 min] to yield the product as a clear oil (36 mg, 43%
yield). LRMS-LC/MS (m/z): 1322.38 [M + H]+.
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(2R,5S,8S,12S,15S,18S)-2-((11S,13R)-15-(2-((1R,3R)-1-Acetoxy-3-((2S,3S)-N((Butyryloxy)methyl)-3-methyl-2-(1-methylpiperidine-2-carboxamido)pentanamido)-4methylpentyl)thiazol-4-yl)-13-(4-hydroxybenzyl)-11-methyl-7,10,15-trioxo-6-oxa-2,3-dithia8,9,14-triazapentadecyl)-8-amino-5,12-bis(carboxymethyl)-18-(3-(2-(2-(3-((2(cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)propanamido)ethoxy)
ethoxy)propanamido)-15-(3-guanidinopropyl)-4,7,11,14,17-pentaoxo-3,6,10,13,16pentAZMaicosanedioic acid, 2.6.

A solution of saturated sodium bicarbonate (10 mL) in distilled water was bubbled with
argon continuously for 30 min. Compound 2.5 (1.2 mg, 0.0009 mmol) was dissolved in argonpurged HPLC grade water (2.0 mL) and the pH of the reaction mixture was increased to 7 using
the argon-purged sodium bicarbonate solution. A solution of disulfide activated-tubulysin B (2.2),
supplied by Endocyte, Inc. (1.27 mg, 0.0012 mmol) in THF (0.5 mL) was then added to the
reaction mixture. The progress of the reaction was monitored using LCMS, and after stirring for
30 min, the reaction was found to reach completion. Compound 2.6 was purified by RP-HPLC [A
= 2 mM ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 100% B in 30
min, retention time: 23.4 min] to yield the requisite product. LRMS-LC/MS (m/z): 1134.57 [half
mass].
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2.2.2.3 Synthesis of a Hydrophilic FBSA for Use as a Competition Ligand

((2S)-2-amino-3-(3-carboxy-2-(2-(3-carboxy-2-(3-(2-(2-(3-((2-(Cyclooctylamino)-3,5,6trifluoro-4-sulfamoylphenyl)sulfonyl)propanamido)ethoxy)ethoxy)propanamido) propanamido)5-guanidinopentanamido)propanamido)propanoyl)-L-aspartic acid, 2.7.

Compound 2.7 was synthesized by the following solid phase methodology: L-aspartic acid
β-tert-butyl ester 2-chlorotrityl resin (100 mg, 0.64 mmole/g) was swollen with 3 mL of
dichloromethane (DCM) followed by 3 mL of dimethylformamide (DMF). After swelling the resin
in DMF, a solution of Boc-DAP(Fmoc)-OH (54.6 mg, 0.128 mmol), HATU (60.8 mg, 0.16 mmol)
and DIPEA (0.056 mL, 0.32 mmol) in DMF (3 mL) was added. Argon was bubbled for 2 h, and
resin was washed with DMF (3 x 3 mL) and IPA (3 x 3 mL). The Fmoc was removed with a
piperidine solution (20% in DMF, 3 x 5 mL) and the resin was washed with DMF (3 x 3 mL) and
IPA (3 x 3 mL). The other residues were added in using the same stoichiometry. Compound 2.7
was cleaved from the resin using a TFA:TIPS:H2O:EDT (95:2.5:2.5:2.5) and concentrated under
vacuum. The concentrated product was precipitated in diethyl ether and dried under vacuum.
Crude conjugate was purified by RP-HPLC [A = 20 mM ammonium acetate buffer (pH 7.0), B =
CH3CN, solvent gradient: 0% B to 60% B in 30 min, retention time: 18.0 min] to yield the product
as a clear oil (62%). LRMS-LC/MS (m/z): 1219.09 [M + H]+.
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2.2.2.4 Synthesis of a FBSA-DM4 Conjugate

(2R,5S,8S)-8-Amino-5,12-bis(carboxymethyl)-2-(((5-((1-(((10Z,12E)-86-chloro-14-hydroxy85,14-dimethoxy-33,2,7,10-tetramethyl-12,6-dioxo-7-aza-1(6,4)-oxazinana-3(2,3)-oxirana8(1,3)-benzenacyclotetradecaphane-10,12-dien-4-yl)oxy)-1-oxopropan-2-yl)(methyl)amino)-2methyl-5-oxopentan-2-yl)disulfaneyl)methyl)-18-(3-(2-(2-(3-((2-(cyclooctylamino)-3,5,6trifluoro-4-sulfamoylphenyl)sulfonyl)propanamido)ethoxy)ethoxy) propanamido)-15-(3guanidinopropyl)-4,7,11,14,17-pentaoxo-3,6,10,13,16-pentAZMaicosanedioic acid, 2.10

To a solution of 2.5 (9 mg, 0.007 mmol) in DCM (2 mL) was added 2,2'-dipyridyldisulfide
(2.8, 7.40 mg, 0.0462 mmol) and allowed to stir under argon for 10 minutes at room temperature.
The reaction was stirred for 18 hours, the DCM was removed under reduced pressure, and 2.8 was
brought forward to the next step without purification. A solution of saturated sodium bicarbonate
(10 mL) in distilled water was bubbled with argon continuously for 30 min. Compound 2.8 (2 mg,
0.0014 mmol) was dissolved in argon-purged HPLC grade water (0.5 mL) and the pH of the
reaction mixture was increased to 7 using argon-purged sodium bicarbonate. A solution of DM4
(2.9, 1.56 mg, 0.002 mmol) in THF (0.5 mL) was then added to the reaction mixture. The progress
of the reaction was monitored using analytical LCMS, and after stirring for 30 min, the reaction
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was found to reach completion. Compound 2.10 was purified by reverse-phase HPLC [A = 2 mM
ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 100% B in 30 min] to
yield the product as a while solid. LRMS-LC/MS (m/z): 2030 [M + H]+.

2.2.3 Cell Lines and Cell Culture
A549, HT29, and SKRC52 cells were cultured at 37 °C in a humidified, 5% CO2
atmosphere using RPMI-1640 medium containing 10% heat-inactivated fetal bovine serum and
1% penicillin streptomycin.

2.2.4 Animal Models
Female athymic nu/nu mice were purchased from Envigo (Cambridgeshire, United
Kingdom) and housed in a sterile environment on a standard 12 h light-dark cycle and maintained
on normal rodent chow. All animal procedures were approved by the Purdue Institutional Care and
Use Committee in accordance with National Institutes of Health guidelines.

2.3

Results and Discussion

2.3.1 Design and Synthesis of FBSA-Tubulysin B Conjugate
The synthesis and in vitro biological studies of FBSA-based fluorescent SMDCs detailed
in Chapter 1 was successfully demonstrated in in vitro cell models suggesting that a FBSA-based
CAIX therapeutic SMDC would show similar promise. As shown in Scheme 2.1, the PEG2 linker
was chosen for the earliest iteration of the therapeutic FBSA SMDCs based upon how it exhibited
the highest apparent binding affinity of the various linker lengths tested in the various FITC
SMDCs (Table 1.1).
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Scheme 2.1 Synthesis of FBSA-PEG2-TubB

The design of the therapeutic SMDC was intended to function as an intermediary for a
divergent synthesis of di-sulfide linked cytotoxic cargo as well as a function as a precursor for a
SPECT/CT imaging agent. That is, the cysteine-aspartic acid-2,3-diaminopropionic acid (C-DDap) motif is an established linear chelator of the SPECT/CT radionuclide 99mTc.87 This divergent
synthetic approach allows for more synthetic ease and is more environmentally friendly by
designing multiple functions into the same synthetic intermediates.
After successfully completing the synthesis of the molecule, the biological evaluation of
the FBSA-PEG2-TubB, 2.3, was carried out as detailed in Section 2.3.2. However, despite having
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a hydrophilic linker composed of several PEG units, and several charged moieties (e.g., the
aspartic acid, Dap, and cysteine side chains), the large hydrophobic regions of the conjugate (e.g.,
cyclooctane ring and the tubulysin cargo) compromised the solubility of the conjugate and was
determined to be a limitation of this molecule in spite of it exhibiting favorable biological activity.
For context, a 1 mM stock solution of 2.3 in PBS (pH 7) required nearly 50% DMSO to maintain
solubility. While this was sufficient solubility for in vitro studies, after a pilot in vivo study was
performed, it was determined that the therapeutic FBSA tubulysin conjugates should be redesigned
to exhibit more favorable aqueous solubility.
To confer additional solubility, the linker of 2.3 was redesigned to have varying positive
and negatively charged amino acids. As shown in Scheme 2.2, the overall synthetic scheme and
structure of the molecule was maintained because of the synthetic and biological success of 2.3.
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Scheme 2.2 Synthesis of a Hydrophilic FBSA-Tubulysin B Conjugate
SPPS strategy used to synthesize FBSA-PEG2-D-R-D-Dap-D-C-Tubulysin B (2.6). Reagents and
conditions: (a) Fmoc-Asp(OtBu)-OH, HATU, DIPEA, DMF, 2h; (b) 20% piperidine/DMF, rt, 3
x 10 min; (c) Fmoc-Dap(Boc)-OH, HATU, DIPEA, DMF, 2h; (d) 20% piperidine/DMF, rt, 3 x
10 min; (e) Fmoc-Asp(OtBu)-OH, HATU, DIPEA, DMF, 2h; (f) 20% piperidine/DMF, rt, 3 x 10
min; (g) Fmoc-Arg(Pbf)-OH, HATU, DIPEA, DMF, 2h; (h) 20% piperidine/DMF, rt, 3 x 10
min; (i) N-amido-PEG₂-acid, HATU, DIPEA, DMF, 2h; (j) 20% piperidine/DMF, rt, 3 x 10 min;
(k) FBSA-COOH, HATU, DIPEA, DMF, 2h; (l) TFA:TIPS:H2O:EDT (95:2.5:2.5:2.5), 3 x 15
min; (m) 2.2, NaHCO3, THF/H20 (1:1), rt, 30 min.

Instead, 2.6 was designed to have an aspartic acid-arginine-aspartic acid motif inserted
before the PEG2 linker. This design ensured that new amino acid side chains would be sufficiently
far away from the tunnel leading to the CAIX active site to avoid any interactions with the CAIX
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surface that might negatively affect the binding ability of the FBSA binding moiety. After addition
of these molecules, the water solubility of the final tubulysin b conjugate 2.6 was effectively
doubled.
The FBSA molecule with a free acid moiety (1.4) was employed for use as a competition
control molecule for several in vitro experiments shown in Chapter 1. Its inherent water
insolubility was mitigated by formulation of the stock solutions in 100% DMSO, followed by
dilution into the cell culture media or buffers used for the experiments. Because the intravenous
injection of high levels of DMSO into mice is not preferred, the synthesis of a hydrophilic FBSAbased competition molecule was undertaken as shown in Scheme 2.3.

Scheme 2.3 Synthesis of a Hydrophilic FBSA (FBSA-PEG2-D-R-D-Dap-D) for Use as a
Competition Ligand

This competition molecule was designed to have a very similar structure to that employed
in 2.6 with one important difference. Because this molecule would not have a disulfide linked
cargo, the use of a terminal cysteine in the linker was not necessary and was eliminated out of
concern that the free thiol would be reactive if injected in the bloodstream; instead, the linker was
terminated with an aspartic acid. The final water solubility of 2.7 was extraordinary and it was
highly water soluble. The highest solubility tested was 100 mM in 100% PBS at pH 7 and it was
used for all further biological testing in cells and mice.
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In order to demonstrate the therapeutic universality of the FBSA conjugates, an alternative
cytotoxic cargo was employed. As shown in Scheme 2.4, the same structure of the targeting moiety
and linker was used. However, instead of tubulysin b, the conjugate 2.10 containing an alternative
therapeutic cargo (the maytansinoid DM4) was synthesized for use in biological evaluation of
CAIX-targeted SMDCs.

Scheme 2.4 Synthesis of a FBSA-DM4 Conjugate
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2.3.2 Biological Evaluations of FBSA Therapeutic Conjugates

2.3.2.1 In Vitro Evaluation of a FBSA-Tubulysin B and DM4 Conjugates
The in vitro potency and specificity of the final products (2.23, 2.6, and 2.10) were
evaluated in the stably transfected HEK293 cells using a 3H-thymidine incorporation assay. For
example, as shown in Figure 1.1, compound 2.6 successfully killed these CAIX-transfected cells
with an IC50 of 1.05 ± 0.01 nM. The DM4 compound was tested for in vitro activity (data not
shown) but exhibited less potency and therefore was not selected for further study for in vivo
studies.
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Figure 2.1 In Vitro Evaluation of a Hydrophilic FBSA-Tubulysin B Conjugate

2.3.2.2

In Vivo Pilot Study of a FBSA-PEG2-Tubulysin B Conjugate
The in vivo efficacy of FBSA-based tubulysin B conjugates was first evaluated using 2.3.

Although this conjugate was eventually redesigned to increase water solubility, a small pilot study
was performed on female athymic nude mice bearing 100-200 mm3 HT29 tumor xenografts.
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Compound 2.3 was formulated for injection into the lateral tail vein of mice by diluting it into PBS
(pH 7.4) with no more than 20% DMSO in a total injection volume of 100 μL at an effective dose
of 2 μmole/kg treated three times per week (TIW). This initial study was performed on five mice
divided into 2 groups: 3 treated at 2 μmole/kg TIW and 2 competition mice treated TIW with 2
μmole/kg in addition to 200 μmole/kg of 2.7 premixed and injected together as mixture.
As shown in Figure 2.2, the treatment group (green triangles) showed significant and
drastic reduction of the tumor volume within approximately seven days. Importantly, the
competition control group (red circles) exhibited inhibited growth of the tumor volume suggesting
that the cytotoxic effects of the tubulysin was due to the receptor-mediated delivery to the CAIX
expressing HT29 tumor cells present in the xenograft. While the tumor volumes data showed that
FBSA-targeted tubulysin SMDCs exhibit efficacy, the whole body masses suggested that there
may be toxicity associated with the 2 μmole/kg TIW treatment regimen. In particular, Figure 2.2
shows that by day 7 of the study, the body masses of the treatment group (green triangles) had lost
10% of their starting values. Conversely, the competition group (red circles) did not exhibit any
appreciable gross body mass loss. Note that whole body mass measurements are a common
measure of gross toxicity in the evaluation of novel therapeutic compounds in xenograft efficacy
studies. The loss of more than 20% of the starting body mass is often used as a humane endpoint
in xenograft studies because it indicates an adverse event (i.e., the treatment has resulted in general
toxicity in the animal).97 The dosages selected for this study were used in previous studies of
ligand-targeted tubulysin B conjugates for both CAIX83 as well as other receptors.98
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Figure 2.2 Pilot study of FBSA-PEG2-TubB in HT29 Xenografts

2.3.2.3 In Vivo Dose Escalation of a Hydrophilic FBSA-Tubulysin B Conjugate
Encouraged by how the pilot study performed on 2.3 demonstrated anti-tumor activity, the
FBSA-TubB conjugate with superior hydrophilicity (compound 2.6) was chosen for a dose
escalation study to determine the maximum tolerated dose (MTD). This study was performed by
treating HT29 xenograft-bearing mice with increasing concentrations of 2.6 TIW; the doses
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selected were 0.25, 0.5, 1, 1.25, 1.5, and 2.0 μmol/kg with one mouse per group/concentration. In
the interest of minimizing the time-frame required to detect tumor reemergence, after the tumor
was eliminated the mice were treated with only one additional dose before treatment cessation.
The mice were then monitored for tumor reoccurrence.
As shown in Figure 2.3, the dosage range selected for this study was successful in that, at
the lowest dose it was unable to shrink the tumors, but at the highest dose, the tumors were rapidly
eliminated. The last day of treatment was Day 6, 8, 12 and 14 for the mice treated with 2, 1.5, 1,
and 0.5 μmol/kg, respectively. Note that since the tumor in the mice treated with 0.25 μmol/kg
did not shrink, the treatment regime was not terminated throughout this study. Doses 2, 1.5, and 1
µmole/kg all shrunk tumors equally fast, but 1 µmole/kg shows tumor reemergence starting on day
16. The tumors in the mice treated with 1.5 and 2 µmole/kg were completely eliminated after Day
6 and remained so for the remainder of the study.
In addition to determining the MTD and the lowest dose of 2.6 to eliminate the tumor, the
other endpoint of this study was to determine the doses which were non-toxic to the mice as
determined by the body masses. An ideal dose would rapidly and permanently eliminate the tumor
without showing any body loss or other signs of toxicity. As shown in the second part of Figure
2.3, the two top doses administered to the mice (1.5 and 2 µmole/kg) both exhibited reversible loss
of body mass, with the highest dose exhibiting the greatest body mass loss. A dose of 1.25
µmole/kg was selected for a larger study discussed in sections 2.3.2.4 and 2.3.2.5.
There are several key aspects in this study worth noting. First, the linker was changed in
between the pilot study (2 µmole/kg TIC of 2.3) and the dose escalation study (various doses of
2.6). The linker employed in 2.6 effectively doubled the aqueous solubility and could have
potentially drastically altered the bioavailability and anti-tumor efficacy in vivo. However, the
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tumors were drastically shrunk for this dose (and the several other lower dosage levels as well).
Another interesting outcome from this study is that the toxicity was still present in the higher
doses—in spite of the potential for the structural changes to alter the biodistribution pattern (i.e.,
the increased hydrophilicity of 2.6 could have altered its metabolism and eventual excretion
patterns).
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Figure 2.3 Dose escalation in vivo efficacy of FBSA-PEG2-TubB in HT29 xenografts
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2.3.2.4 In Vivo Evaluation of a Hydrophilic FBSA-Tubulysin B Conjugate in a HT29
Xenograft Model
After determining that a dose of 2.0 μmol/kg produces toxicity in mice, 1.25 μmol/kg TIW
was selected as a conservative dosage regime that would exhibit rapid, selective, and nontoxic
elimination of the tumors. As shown in Figure 2.4, the aforementioned treatment regimen caused
dramatic tumor shrinkage when no competing ligand was added (green triangles). However, upon
co-injection of 100-fold excess the competition ligand 2.7, tumor growth increased to the rate seen
in untreated controls. These data demonstrate that treatment of HT29 tumors was CAIX-specific,
and that little or no cancer cell death derived from nonspecific extracellular release of nontargeted
drug. This lack of significant premature drug release was further confirmed by demonstrating that
conjugate-treated animals show no weight loss—an outcome that would not have been expected if
the highly toxic free tubulysin were released systemically during transit to the tumor.

3

T u m o r V o lu m e ( m m )

52

C o m p o u n d 2 .6
C o m p e t i t io n C o n t r o l
V e h ic le

1500
1000
500
0
0

5

10

15

20

P e rc e n t C h a n g e in B o d y M a s s

D a y s A f t e r S t u d y In it i a t io n

20
10
0
5

10

15

20

-10
-20

D a y s A f t e r S t u d y In i t ia t io n

Figure 2.4 In Vivo Antitumor Efficacy of 2.6 in HT29 Xenografts
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2.3.2.5 In Vivo Evaluation of a Hydrophilic FBSA-Tubulysin B Conjugate in a A549
Xenograft Model
The previous data detailed the successful demonstration of the efficacy of FBSA-targeted
tubulysin B conjugates are efficacious in a model of human colon cancer using xenografts derived
from the HT29 cancer cell line. However, since CAIX is expressed in a multitude of human cancer
types, it would be advantageous to demonstrate antitumor efficacy in xenograft derived from a
different human cancer cell line. Based upon the screening performed using the FBSA-FITC
molecules discussed in Chapter 1, the human lung adenocarcinoma cell line was chosen for a
second, smaller-scale study of 2.6. As shown in Figure 2.5, while using the same conditions as
employed for the HT29 study, 1.25 µmole/kg of 2.6 showed similar efficacy and specify in the
A549 xenografts while the whole body masses indicated that there was no significant toxicity
present. These data successfully demonstrate that the efficacy of 2.6 in several CAIX positive
human cancer cell lines.
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Figure 2.5 In Vivo Antitumor Efficacy of 2.6 in A549 Xenografts

2.4

Conclusion
Because of its upregulation in many cancers, carbonic anhydrase IX has attracted

increasing interest as a possible target for ligand-targeted therapeutic interventions in solid tumors.
For example, Cazzamalli et al.99 and Krall et al.82 have used the FDA-approved small molecule
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CAIX inhibitor, acetazolamide (Ki ~ 25 nM), as a targeting ligand to deliver cytotoxic compounds
including monomethyl auristatin E (MMAE), PNU-159682, maytansine, and duocarmycin.
Similarly, Lv et al., exploiting a tubulysin conjugate of a different small molecule inhibitor (KI ~
7.8 nM), reported only stable disease when dosed TIW at 2 μmol/kg for three weeks. 83 Because
off-tumor toxicity commonly limits the amount of drug that can be administered, we reasoned that
use of a much higher affinity targeting ligand for delivery of our cytotoxic payload might allow a
more complete response, since saturation of tumor receptors at much lower conjugate
concentrations should reduce off-target toxicities associated with unwanted drug release in healthy
tissues. For this purpose, we scrutinized the literature for high affinity inhibitors of CAIX and
found the fluoro-benzosulfonamide developed by Dudutiene and coworkers86 to bind CAIX with
much higher affinity and specificity. Not surprisingly, conjugation of this inhibitor to tubulysin B
yielded better responses in tumor-bearing mice implanted with multiple tumor types at a dose
lower than was achieved with earlier tubulysin B conjugates. While Janoniene and coworkers
previously modified a porous silicon nanosystem to display FBSA on the surface to achieve CAIX
targeting, the work described in this chapter is the first use of FBSA as the targeting moiety in a
therapeutic small molecule drug conjugate for CAIX positive tumors.100
While most previous ligand-drug conjugates developed in the Low lab have been targeted
to tumor-specific receptors that readily internalize (i.e. and thereby delivering their cargoes into
intracellular compartments), the FBSA ligand used in this study was not found to internalize. The
question therefore arises whether this inability to rapidly deliver an attached drug into the target
cell’s interior might compromise the ligand-drug conjugate’s potency. While delivery of a ligandtargeted drug to an endocytosing receptor is always preferred,101 previous work in the Low
laboratory has shown that even a non-internalizing receptor can be exploited for potent tumor-
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specific cytotoxicity.102 Virtually all cell surface receptors naturally internalize during the normal
process of membrane recycling (which occurs within hours in many cells),103, 104 and even payloads
that are not internalized can be engineered for facile cell surface release if they are conjugated to
their tumor targeting ligands via a disulfide bond.99, 102 Thus, because many cancer cells upregulate
a trans-plasma membrane redox pathway that continuously generates extracellular reducing
power,105 disulfide bonds are much more rapidly reduced in a tumor microenvironment than in the
extracellular milieu of healthy tissues.106, 107 Because the targeted drugs employed in our studies
are all naturally membrane permeable, their probabilities of entering a cancer cell over a normal
cell must be very high. Thus, assuming the average diameter of a tumor nodule to be ~1 cm and
the average diameter of a cancer cell to be ~20 μm, a drug released near the middle of the nodule
would have to pass by ~250 cancer cells before it could leave the tumor mass. This must increase
the probability that the cytotoxic warhead will preferentially kill a cancer over a normal cell.
FBSA targeting of CAIX can also be used for applications other than the targeted delivery
of tubulysin B to CAIX positive cells. Because some of the cells that are present in hypoxic regions
of solid tumors may slowly divide, there are cytotoxic cargos other than tubulysin B that merit
further exploration, including spliceostatins and pyrrolobenzodiazepines. Additionally, FBSA
could be used to target therapeutic radionuclides to CAIX positive cancers. Beyond the therapeutic
applications, there are also targeted imaging applications, including FBSA-targeted fluorescent
dyes for the fluorescence-guided surgical resection of CAIX positive tumors and FBSA-targeted
PET and SPECT/CT radioimaging agents for whole body diagnosis and monitoring of cancer.
Additionally, while compound 2.6 has the potential to be a powerful therapeutic compound,
it could also provide a substantial contribution to a cocktail of ligand targeted conjugates that cover
a wide range of human cancers. For example, the quintessential SMDC target is the folate receptor

57
which is prominently overexpressed in numerous cancers including 80-90% ovarian,108 78-80%
breast,109 33-44% colon,110 and 83% lung cancers.111 In addition, the prostate-specific membrane
antigen (PSMA) receptor has shown to be expressed in 80% of prostate cancers112 as well as the
neovasculature of many solid tumors.113 CAIX is upregulated in 71% of clear cell renal
carcinomas,52 14% breast cancers,114 and the hypoxic regions of many other cancers. Future work
could focus on formulating a cocktail to target different receptors (e.g., CAIX, folate, and PSMA)
to eliminate a broad range of tumor types in a safe and effective manner.
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DEVELOPMENT OF A CARBONIC ANYDRASE IX
TARGETED PET/CT IMAGING AGENT

3.1

Introduction
Positron emission tomography (PET) imaging is widely used in the clinic for the diagnosis

and treatment of human cancers. After injecting the PET imaging agent into a patient, the
radionuclide emits a positron which can travel up to several millimeters before colliding with an
electron in the tissue of the patient, emitting pair of 511 KeV photons which are detected by the
detection elements of the PET.115 Because of the poor resolution of PET, the images are often
acquired in conjunction with computed cytometry (CT), creating a superimposed PET/CT image.
The most popular PET radioisotopes are
(T1/2 = 12.7 hours),

13

18

F (T1/2 = 110 minutes),

N (T1/2 = 10 minutes), 89Zr (3.3 days),

68

11

C (T1/2 = 20 minutes),

Ga (68.1 mintues), and

124

64

Cu

I (T1/2 =

4.18 days).116 The isotope is chosen based upon the application; for example, for long-circulating
antibody-based radioimaging conjugates, a longer half-life is required (e.g., 89Zr, 124I).117, 118 The
most prominent PET imaging contrast agent is

18

F-fluorodeoxyglucose (FDG) which is an

18

F-

labeled glucose which accumulates in malignant tissues due to the increased glucose metabolism
present in many human cancers.119
In order to facilitate the translation of an FBSA-targeted PET agent into the clinic, the
chelation chemistry was designed to be as straightforward as possible, yield products with high
radiochemical yields, and, ideally, chelate multiple clinically relevant radionuclides. The
NODAGA chelation group was chosen because it allows for the chelation of copper-64 and
gallium-68. Copper-64 has a half-life of 12.7 hours, making it amenable for overnight transport.
However, it is less clinically attractive because of its longer half-life (shorter half-lives are
preferable to minimize patient exposure). However, gallium-68 has a much shorter half-life of 67.7
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minutes, which makes is difficult to transport but much more attractive for clinical applications.
Since NODAGA is able to chelate both copper-64 and gallium-68 with similar efficacy, copper64 was chosen for preclinical studies because of its availability for shipment to the Purdue campus.
In this chapter, the successful synthesis of a FBSA-PET imaging conjugate is reported in addition
to its purification and characterization. A series of formulation optimization experiments were then
performed, yielding chelation conditions with high radiochemical purity. The in vitro binding of
FBSA-NODAGA in two human cancer cell lines was assessed and the in vivo efficacy was
demonstrated with tumor-specific uptake of the FBSA-PET conjugate in several xenograft models.

3.2

Materials and Methods

3.2.1 Chemicals and Materials
1,2-Diaminoethane trityl polystyrene resin, DMF, TFA, DIPEA, piperidine, and DCM
were purchased from Sigma Aldrich (St. Louis, MO). NODAGA-NHS was purchased from
obtained from CheMatech (Dijon, France). Copper-64 was purchased as a copper chloride eluted
with 0.1 N HCl with a radionuclidic purity of >99%.
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3.2.2 Synthesis of FBSA-Based PET Imaging Conjugates

N-(2-Aminoethyl)-3-(2-(2-(3-((2-(cyclooctylamino)-3,5,6-trifluoro-4sulfamoylphenyl)sulfonyl)propanamido)ethoxy)ethoxy)propanamide (3.1)
Compound 3.1 was synthesized by the following solid phase methodology: After swelling
the 1,2-diaminoethane trityl polystyrene resin (100 mg, 1.7 mmol/g) with DMF (3 mL) and DCM
(3 mL), a solution of 1-(9H-fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azatridecan-13-oic acid (136 mg,
0.34 mmol), HATU (162 mg, 0.43 mmol) and DIPEA (0.09 mL, 0.51 mmol) in DMF (3 mL) was
added. The reaction mixture was bubbled with argon for 2 h, and resin was washed with DMF (3
x 3 mL) and DCM (3 x 3 mL). The Fmoc was removed with a piperidine solution (20% in DMF,
3 x 5 mL) and the resin was washed with DMF (3 x 3 mL) and DCM (3 x 3 mL). A solution of 3((2-(cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)sulfonyl)propanoic acid (179 mg, 0.425
mmol), HATU (162 mg, 0.43 mmol) and DIPEA (0.09 mL, 0.51 mmol) in DMF was added. Argon
was bubbled for 2 h, and resin was washed DMF (3 x 3 mL) and DCM (3 x 3 mL). Compound
3.1 was cleaved from the resin using a TFA:TIPS:H2O:EDT cocktail (95:2.5:2.5:2.5) and
concentrated under vacuum. The concentrated product was precipitated in diethyl ether and dried
under vacuum. Crude conjugate was purified by reverse-phase HPLC [A = 2 mM ammonium
acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 40% B in 30 min] to yield the
product as a white solid. LRMS-LC/MS (m/z): 674.3 [M + H]+.
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2,2'-(7-(21-Carboxy-1-((2-(cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)

sulfonyl)-

3,13,18-trioxo-7,10-dioxa-4,14,17-triazahenicosan-21-yl)-1,4,7-triazonane-1,4-diyl)diacetic acid
(3.2)
To a solution of 3.1 (3 mg, 0.003 mmol) in DMF (1 mL) was added 2,2'-(7-(1-carboxy-4-((2,4dioxopyrrolidin-1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl)diacetic acid (NODAGA-NHS,
1.4 mg, 0.009 mmol) and DIPEA (0.0016 mL, 0.034 mmol) and stirred for 1 hour at room
temperature. The crude reaction mixture was purified reverse-phase HPLC [A = 2 mM ammonium
acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 20% B in 30 min] to yield the
product as a white powder (83% yield). LRMS-LC/MS (m/z): 1031.5 [M + H]+.

3.2.3 General Procedure for Radiolabeling of Compound 3.2 with 64Cu
Radiolabeling was carried out using

64

CuCl2 in 0.1 N HCl by mixing it with a 50-fold

excess of compound 3.2 in a sodium acetate buffer (pH 10.5) and incubating at room temperature
for a minimum of 15 minutes prior to use. To assess the radiochemical purity of the chelation, the
solution was analyzed using an Agilent 1260 Infinity II equipped with a LabLogic Flow-RAM
radio-HPLC detector with Laura Academia software and a C18 column using the following
method: solvent A = 0.1% TFA, solvent B = ACN, solvent gradient: 0% B to 100% B in 15 min].
After verification that the radiochemical purity was > 95%, the radiolabeled 3.2 was used without
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purification after diluting into the appropriate solvent (cell culture media for in vitro experiments)
and (PBS, pH 7.4 for in vivo experiments).

3.2.4 Cell Lines and Cell Culture
A549, HT29, and SKRC52 cells were cultured at 37 °C in a humidified, 5% CO2
atmosphere using RPMI-1640 medium containing 10% heat-inactivated fetal bovine serum and
1% penicillin streptomycin.

3.2.4.1 In Vitro Binding Affinity Protocol
SKRC52, HT29, A549 cells (~0.25 x 106) were seeded in a 24-well plate and allowed to
grow overnight. Fresh medium containing increasing concentrations of radiolabeled 3.2 in the
presence or absence of 100-fold excess FBSA competition compound (1.4) was added. All
concentrations were examined in duplicate or triplicate. After incubating for 1 h at 25 °C, cells
were washed with PBS (3 x 0.5 mL). To each well was added 0.5 M NaOH. After 10 min, 0.45
mL of the NaOH was removed and the radioactivity was measured with a γ-counter (Packard,
Packard Instrument Company). The apparent binding affinity was calculated by plotting the bound
radioactivity versus the concentration of 3.2 with GraphPad Prism 4.

3.2.5 Animal Husbandry
Female athymic nu/nu mice were purchased from Envigo (Cambridgeshire, United
Kingdom) and housed in a sterile environment on a standard 12 h light-dark cycle and maintained
on normal rodent chow. All animal procedures were approved by the Purdue Institutional Care and
Use Committee in accordance with National Institutes of Health guidelines.
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3.2.6 Whole-body Imaging and Biodistribution of FBSA-PET Agents in Mouse Xenograft
Models
SKRC52, HT29, or A549 cells (~3 x 106 cells per mouse) were injected subcutaneously
into the shoulders of female athymic nu/nu mice. Growth of the tumors was measured in two
perpendicular directions and the volumes of the tumors were calculated as 0.5 × L ×W2 (L =
longest axis and W= axis perpendicular to L in millimeters). Once tumors reached a minimum of
500 mm3 in volume, animals were injected with 64Cu-labeled 3.2 (250 μCi) in PBS (100 μL, pH
7.4) via tail vein injection. To obtain whole-body images, mice were anesthetized with isoflurane
and images were acquired with a Kodak Imaging Station (In-Vivo FX, Eastman Kodak Company)
in combination with CCD camera and Kodak molecular imaging software (version 4.0) with the
kidneys shielded. Radioimages were acquired using the following parameters: radio isotope
illumination source, 3 min acquisition time, f-stop = 4, focal plane = 5, FOV = 160, binning = 8.
White light images were acquired using the following parameters: white light transillumination
illumination source, 0.175 s acquisition time, f-stop = 16, focal plane = 5, FOV = 160, and no
binning. After acquiring the whole-body imaging, the mice were sacrificed with CO2 asphyxiation
and, following necropsy, the tissues were placed into preweighed γ-counter tubes. The
radioactivity of the tissues and a fraction of the injected dose was measured in a γ-counter
(Packard, Packard Instrument Company). Count per minute (CPM) values were corrected for
decay times, and the results were calculated as percent of the injected dose per gram (% ID/g) of
wet tissue.
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3.3

Results and Discussion

3.3.1 Design and Synthesis of FBSA-Radioimaging Agents
Building upon the success of FBSA-based SMDCs for therapeutic and fluorescence-based
imaging agents, the evaluation of FBSA-PET imaging agents was undertaken next. PET imaging
is a primary method used in the clinic to for the diagnosis of malignancies as well as monitoring
the disease while undergoing treatment.120 The selection of copper-64 nuclide was determined
primarily basics upon logistical concerns as previously outlined in the introduction to this chapter.
After selection of the correct radionuclide for the purpose of the FBSA-based targeted delivery,
the NODAGA chelating group was chosen for its favorable chelation characteristics. That is, of
central importance to the design of the FBSA-PET imaging agents was its eventual translatability
to the clinic. To facilitate this, selecting a chelation protocol with high radiochemical purity at
room temperature with minimal formulation requirements was desirable. The NODAGA chelation
of the copper-64 occurs within 10-15 minutes at room temperature in aqueous solutions, meeting
the pre-established desirable characteristics for an ideal FBSA-PET radioimaging chelation group.
The synthesis of the FBA-PEG2-NODAGA conjugate was carried out as shown in Scheme
3.1. The overall design of the conjugate embodies the lessons learned by previous studies of
fluorescent and therapeutic conjugates. In particular, the 20 Å linker was maintained in 3.2 by
employing the PEG2 linker. However, since the NODAGA chelator was commercially available
as an NHS ester, the previous FBSA intermediates (possessing a terminal thiol) were not amenable
for NHS coupling, the FBSA-PEG2 core structure was redesigned to possess a terminal amino
functional group (3.1) to react with the NHS-NODAGA.
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Scheme 3.1 Synthesis of a FBSA-PEG2-NODAGA Conjugate

As previously discussed, the NODAGA chelation group was selected due to its favorable
chelation conditions with copper-64 and gallium-68. However, because the chelation of copper64 for a SMDC with NODAGA may perform different than reported chelation conditions, a series
of formulation experiments were undertaken to screen optimize the chelation of 3.2 with copper64. After screening for several variables including time, concentration, and pH and measuring the
radiochemical purity using radio-HPLC, the following conditions listed in Table 3.1 were found
to be the optimal chelation conditions. As shown in Figure 1.1, the radiochemical purity of 3.2 was
determined to be <95% by radio-HPLC. Note that the retention time of free copper-64 is the same
the solvent front (~2 min), however the radiochromatogram shows that the only peak corresponds
to the retention time of 3.2 (8.6 mins).
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Table 3.1 Optimized Chelation Conditions of FBSA-NODADA with Copper-64

Concentration
Buffer
Temperature
Time

< 100 μM
Acetate Buffer (0.5
mM, pH 10.5)
Room Temperature
> 10 min

Scheme 3.2 Chelation of 64Cu with Compound 3.2
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Figure 3.1 Evaluation of the Radiochemical Purity of FBSA-PEG2-NODAGA-64Cu

3.3.2

In Vitro Binding of FBSA-NODAGA-64Cu
The first measure of biological activity of the FBSA-PET agents was performed in in vitro

using the same cell lines and similar conditions to those established with the FBSA-FITC (Chapter
1). As can be seen in Figures 3.2 and 3.3, the apparent binding affinity of 3.2 was established using
SKRC52 and A549 cells as a low nM value and reaching saturation at approximately 75 nM.
Importantly, the competition controls (cells treated with increasing concentrations of 3.2 with 100fold excess of the competition ligand 2.7) showed significantly less bound radioactivity,
establishing that that the binding of 3.2 to the cells was a receptor-specific event.
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Figure 3.2 In Vitro Binding of FBSA-PEG2-NODAGA-64Cu in SKRC52 Cells
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Figure 3.3 In Vitro Binding of FBSA-PEG2-NODAGA-64Cu in A549 Cells

3.3.3 In Vivo Evaluation of FBSA-NODAGA-64Cu
After optimizing the copper-64 chelation conditions and confirming the low nM binding
affinity of 3.2-64Cu to CAIX-positive cell lines, the next step was to assess the in vivo
biodistribution patterns. After chelation with copper-64, 250 μCi of 3.2 was injected into the tail
vein of mice bearing xenografts derived from the A549 cell line. At various time points shown in
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Table 3.2, the tissues were removed from the mice (n=1 per time point), weighed, and the
radioactivity was quantified on a gamma counter. Note that copper-64 emits gamma radiation at
511 keV in 36% abundance, it is possible to use gamma detection methods.121
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Figure 3.4 Biodistribution Time-Course Study of Compound 3.3 in Mice with A549 Xenografts

Table 3.2 Tumor-to-Tissue Ratios in a Time-Course Study of 3.2-64Cu in A549 Xengrafts
Time
(hr)
1
3
6
9
12
15
18

Tumor:Stomach Tumor:Kidneys
0.1
0.1
1.3
4.0
1.8
4.5
6.3

0.3
0.2
1.8
3.6
2.3
2.8
2.2

As can be seen in Table 3.2, initially the uptake of the conjugate is very high in the stomach
and kidneys. It is not until six hours post-injection, that the tumor began to showing higher tissue
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uptake than the stomach and kidneys. However, the highest tumor-to-tissue ratio was shown at
nine hours. At all other later times tested, the tumor maintained this higher uptake.
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Figure 3.5 Biodistribution of FBSA-NODAGA-64Cu in an A549 Xenograft Model

The full tissue biodistribution of 3.2-64Cu is shown in Figure 3.5 at 18 hours post injection.
This experiment was performed at 18 hours primarily for logistical ease after verifying that the
tissue uptake values between 6 and 18 hours do not drastically change. The high tumor uptake is
still maintained at 18 hours and, most importantly, the competition mouse (mice co-injected with
250 μCi of 3.2-64Cu + 100-fold molar excess of the competition molecule 2.7) has a much lower
radiation count at the tumor site than the non-competition mouse. This indicates that 3.2-64Cu is
binding specifically to the tumor cells in a receptor-mediated manner.
An important feature of any new technology is to show that it has efficacy in multiple
experimental models. Building upon the successful evaluation of FBSA-based SMDCs in several
other human cancer lines, it was desirable to test 3.2 in a similar fashion. Figure 3.6 and Figure 3.7
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show the biodistribution data from these experiments using SKRC52 and HT29 xenografts at 18
hours after injection. The SKRC52 experiment was performed with a competition control that
indicated the radioactivity at the tumor was receptor mediated. The HT29 xenografts were not
tested with the competition control. Because the HT29 cells express many fewer CAIX receptors
on the cell surface, the tumor to tissue background ratios are not very good at 18 hours.
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Figure 3.6 Biodistribution of FBSA-NODAGA-64Cu in a SKRC52 Xenograft Model
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Figure 3.7 Biodistribution of FBSA-NODAGA-64Cu in a HT29 Xenograft Model

Figure 3.8 shows the whole-body images of mice bearing with CAIX-positive xenografts
using after injecting FBSA-NODAGA-64Cu (compound 3.2). In particular, it shows a competition
experiment performed with mice bearing SKRC52 xenografts after injecting 250 µCi of 3.2 labeled
with 64Cu and acquiring the whole-body images of the anesthetized mice five hours after injections.
In the case of the experiment shown in the top image of Figure 3.8, the mouse injected with the
targeted PET imaging conjugate (green arrow) shows bright uptake at the tumor site. However the
two mice shown on the left (red arrows) injected with 100-fold excess of the competition ligand
(2.7) in conjugation of the 250 µCi of 3.2 do not exhibit any tumor uptake at the threshold selected
for this image. To confirm this, the tumors were removed from the mice and are shown in the
bottom part of Figure 3.8 and again show higher tumor uptake in the targeted mouse versus the
competition mice.
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Figure 3.8 PET/CT of FBSA-NODAGA-64Cu in a SKRC52 Xenograft Model

To confirm the efficacy of 3.2 in other tumor models, the whole-body images were also
acquired in several other xenograft models. For example, as shown in Figure 3.9, the targeted
mouse (green arrow) shows much higher tumor uptake than that of the competition mouse (red
arrow). This data was also demonstrated in mice bearing HT29 xenografts (data not shown). The
demonstration of this technology in multiple tumor models is in accordance to FBSA-based
SMDCs delivering other imaging cargos.
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Figure 3.9 PET/CT of FBSA-NODAGA-64Cu in an A549 Xenograft Model

3.4

Conclusion
When this project was initiated, there were several design constraints placed upon it to

maximize its translation into the clinic. Of particular importance was that the chelation process
must be as easy as possible and produce products with high radiochemical yields. Additionally,
the chelation group must be able to chelate multiple clinically relevant radionuclides. The
NODAGA chelation group was desirable because it would allow for chelation of copper-64 and
gallium-68. The copper-64’s half-life of 12.7 hours makes it amenable for overnight transport, but
is less clinically attractive because the shorter half-lives are preferable to minimize patient
exposure. However, gallium-68 has a much shorter half-life, which makes it more difficult to
transport but much more attractive for clinical applications. Since NODAGA is able to chelate
both copper-64 and gallium-68 with similar efficacy, copper-64 was chosen for preclinical studies
because of its availability for shipment to the Purdue campus.
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After screening various chelation conditions, the optimized conditions yielded a copper64-labelled 3.2 with a high degree of radiochemical purity (<95% is the standard measure used in
preclinical studies). Future work will be done to formulate compound 3.2 as a lyophilized solid,
allowing the copper-64 and water to be added just prior to injection. This meets the required desire
to make the chelation as facile as possible to facilitate the clinical translatability.
The in vitro efficacy of 3.2 was found to mimic both the fluorescent and therapeutic
experimentally determined values of biological activity. In particular, the measurement of the in
vitro binding affinity of 3.2-64Cu showed single digit nanomolar values in radiobinding affinity
assays using multiple human cancer cell lines. The in vivo efficacy of 3.2-64Cu was demonstrated
in mice bearing CAIX-positive xenografts. There were two primary endpoints in these studies: the
whole-body images and the quantified biodistribution of tissues. The whole-body images
successfully showed the increased tumor uptake of the radiolabeled conjugate and demonstrated
selectivity using the competition controls.
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OPTIMIZATION OF ACETAZOLAMIDE FOR USE AS
A SMALL MOLECULE DRUG CONJUGATE TARGETING LIGAND

4.1

Introduction
Carbonic anhydrase IX (CAIX) is a membrane-bound zinc metalloenzyme that is prevalent

in many human cancers including renal cell carcinomas, colorectal, and lung cancer.

The

overexpression on the membrane of malignant cells and low expression levels on healthy tissues
make CAIX a particularly attractive target for small molecule inhibitors, ADCs, and SMDCs.122
Acetazolamide (AZM, trade name: Diamox) was FDA approved in 1952 for glaucoma. It is also
indicated for acute mountain sickness, high altitude cerebral edema, and hypokalemic periodic
paralysis.123 It is a CAIX competitive inhibitor with a Ki of 25 nM but is also active towards other
carbonic anhydrases including CAXII (Ki= 17 nM) and CAXIV (Ki= 11 nM).124 AZM has also
been widely used as a targeting ligand for SMDC targeting the CAIX receptor delivering
fluorescence imaging,125 radioimaging,76, 126 and therapeutic cargos.82, 107, 127
The repurposing of clinically approved drugs is a popular strategy because of their
established safety profiles.128 Because of the popularity of acetazolamide as a SMDC targeting
moiety, it was hypothesized that it would be advantageous to perform a structure-based design
study of an improved version of acetazolamide to yield better binding affinity and selectivity in
vivo. In this chapter, an in silico based structure-based design experiment yielded a modified
version of acetazolamide that was then tested for in vivo efficacy in whole-body fluorescence
imaging experiments.
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4.2

Materials and Methods

4.2.1 In Silico Design
Molecular modeling of acetazolamide binding was performed using the Schrödinger
product suite (LLC, New York, 2012 product suite (Schrödinger, LLC, New York) using a X-ray
crystal structure of CAIX at 1.95 Å resolution (PDB Code: 5FL6). The CAIX protein structure
was prepared using the Protein Preparation Wizard. After protein preparation, docking was
initiated by generating a Grid file using Receptor Grid Generation panel of Glide and compounds
were docked using the extra precision method.

4.2.2 Chemicals and Materials
H-Cys(Trt)-2-chlorotrityl resin and L-aspartic acid ß-tert-butyl 2-chlorotrityl resins were
obtained from Novabiochem (San Diego, CA). Amino acids were purchased from Chem-Impex
International (Chicago, IL). HATU was obtained from Genscript Inc. (Piscataway, NJ). Sulfuric
acid, MeOH, DMSO, DMF, TFA, IPA, DIPEA, piperidine, DCM, K2CO3, and all other chemical
reagents were purchased from Sigma Aldrich (St. Louis, MO). Amine-coated 24-well microtiter
plates were purchased from BD Biosciences (San Jose, CA). All other cell culture reagents,
syringes, and disposable items were purchased from VWR (Chicago, IL).
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4.3

Synthesis

4.3.1 Synthesis of Acetazolamide-Tryptophan Starting Material

5-Amino-1,3,4-thiadiazole-2-sulfonamide, 4.2
Acetazolamide (4.1, 10 g, 45 mmol) was added hydrochloric acid (30 mL) and ethanol (70
mL) and the mixture was refluxed for 4 hours. After heating, the white solid dissolved into the
solution. The liquids were removed under pressure and the white solid was dissolved in water and
the pH adjusted to 7. The white precipitate was filtered and dried and brought forward without
further purification.

Tert-butyl (S)-3-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-3-oxo-3-((5-sulfamoyl-1,3,4thiadiazol-2-yl)amino)propyl)-1H-indole-1-carboxylate, 4.3
To a solution of Nα-Fmoc-N(in)-Boc-L-tryptophan (351 mg, 0.67 mmol),

1-

[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
(527.77 mg, 1.39 mmol), and N,N-Diisopropylethylamine (0.483 mL, 2.78 mmol) in DMF (3 mL)
was added 4.2 (100 mg, 0.55 mmol) at room temperature under argon gas. The reaction was stirred
for 18 hours before quenching with water and extracted with ethyl acetate (3 x 25 mL). The organic
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layers were combined, washed with brine, and dried over anhydrous sodium sulfate. The solvent
was concentrated under vacuum, and the crude mixture was purified on silica gel using 50% ethyl
acetate/hexanes to obtain 4.3 as a brown oil (156.6 mg, 41% yield). LRMS-LC/MS (m/z): 699.2
[M + H]+.

Tert-butyl (S)-3-(2-amino-3-oxo-3-((5-sulfamoyl-1,3,4-thiadiazol-2-yl)amino)propyl)-1H-indole1-carboxylate, 4.4
To a solution of 4.3 (100 mg, 145.3 mmol) in tetrahydrofuran (20 mL) was added piperidine
(0.015 mL, 145.3 mmol) at room temperature. The reaction was allowed to stir for 1 hr and then
the tetrahydrofuran and piperdine removed under vacuum to give 4.4 as a white solid. This product
was brought forward without purification.

Tert-butyl (S)-3-(2-(8-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)octanamido)-3-oxo-3-((5sulfamoyl-1,3,4-thiadiazol-2-yl)amino)propyl)-1H-indole-1-carboxylate, 4.5
To a solution of Fmoc-8-amino-3 6-dioxaoctanoic acid (128 mg, 0.335 mmol),

1-

[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
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(274 mg, 0.723 mmol), and N,N-Diisopropylethylamine (0.243 mL, 1.40 mmol) in DMF (1.5 mL)
was added 4.4 (130 mg, 0.279 mmol) at room temperature under argon gas. The reaction was
stirred for 18 hours before quenching with water and extracted with ethyl acetate (3 x 10 mL). The
organic layers were combined, washed with brine, and dried over anhydrous sodium sulfate. The
solvent was concentrated under vacuum, and the crude mixture was purified on silica gel using
25% ethyl acetate/hexanes to obtain 4.5 as a light brown solid (464 mg, 56% yield). LRMS-LC/MS
(m/z): 830.4 [M + H]+.

Tert-butyl (S)-3-(2-(8-aminooctanamido)-3-oxo-3-((5-sulfamoyl-1,3,4-thiadiazol-2yl)amino)propyl)-1H-indole-1-carboxylate, 4.6
To a solution of 4.5 (250 mg, 301 mmol) in tetrahydrofuran (80 mL) was added piperidine
(0.030 mL, 301 mmol) at room temperature. The reaction was allowed to stir for 1 hr and then the
tetrahydrofuran and piperdine were removed under vacuum to give 4.6 as a white solid. This
product was brought forward without purification.

81

4.3.1.1

Synthesis of an Acetazolamide-Tryptophan Near-Infrared Imaging Conjugate

2-((E)-2-((E)-2-(4-(3-((8-(((S)-3-(1-(Tert-butoxycarbonyl)-1H-indol-3-yl)-1-oxo-1-((5-sulfamoyl1,3,4-thiadiazol-2-yl)amino)propan-2-yl)amino)-8-oxooctyl)amino)-3-oxopropyl)phenoxy)-3-(2((E)-3,3-dimethyl-5-sulfo-1-(4-sulfobutyl)indolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)3,3-dimethyl-1-(4-sulfobutyl)-3H-indol-1-ium-5-sulfonate, 4.8
To a solution of the near infrared dye 4.7 (10 mg, 0.010 mmol), 1-[Bis(dimethylamino)
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (9.35 mg, 0.025
mmol), and N,N-Diisopropylethylamine (0.005 mL, 0.05 mmol) in DMF (1 mL) was added 4.6
(6.08 mg, 0.010 mmol) at room tempera ture under argon gas. The reaction was stirred for 4 hours
and the crude conjugate was purified by reverse-phase HPLC without workup [A = 2 mM
ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 60 % B in 30 min] to
yield 4.8 as a green solid (13.98 mg, 87% yield). LRMS-LC/MS (m/z): 1606.5 [M + H]+.
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2-((E)-2-((E)-2-(4-(3-((8-(((S)-3-(1H-indol-3-yl)-1-oxo-1-((5-sulfamoyl-1,3,4-thiadiazol-2yl)amino)propan-2-yl)amino)-8-oxooctyl)amino)-3-oxopropyl)phenoxy)-3-(2-((E)-3,3-dimethyl5-sulfo-1-(4-sulfobutyl)indolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4sulfobutyl)-3H-indol-1-ium-5-sulfonate, 4.9
To a solution of 4.8 (5 mg, 0.003 mmol) in water (5 mL) was added trifluoroacetic acid
(0.25 mL). The reaction was stirred for 1 hour and then was purified by reverse-phase HPLC [A
= 2 mM ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 60 % B in 30
min] to yield 4.9 as a green solid (3.57 mg, 79% yield). LRMS-LC/MS (m/z): 1506.4 [M + H]+.
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4.3.1.2 Synthesis of a AZM-NIR Conjugate

(9H-Fluoren-9-yl)methyl (8-oxo-8-((5-sulfamoyl-1,3,4-thiadiazol-2-yl)amino)octyl)carbamate,
4.10
To a solution of Fmoc-8-amino-3,6-dioxaoctanoic acid (254.03 mg, 0.666 mmol), 1[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate
(805 mg, 1.39 mmol), and N,N-Diisopropylethylamine (0.494 mL, 2.775 mmol) in DMF (5 mL)
was added 5-amino-1,3,4-thiadiazole-2-sulfonamide (4.2, 100 mg, 0.555 mmol) at room
temperature under argon gas. The reaction was stirred for 18 hours before quenching with water
and extracting with ethyl acetate (3 x 50 mL). The organic layers were combined, washed with
brine, and dried over anhydrous sodium sulfate. The solvent was concentrated under vacuum, and
the crude mixture was purified on silica gel using 25% ethyl acetate/hexanes to obtain 4.10 as a
light brown solid (254 mg, 84% yield). LRMS-LC/MS (m/z): 544.2 [M + H]+.
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8-Amino-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)octanamide, 4.11
To a solution of (9H-fluoren-9-yl)methyl (8-oxo-8-((5-sulfamoyl-1,3,4-thiadiazol-2yl)amino)octyl)carbamate (100 mg, 0.184 mmol) in tetrahydrofuran (80 mL) was added piperidine
(0.018 mL, 0.184 mmol) at room temperature. The reaction was allowed to stir for 1 hr and then
the tetrahydrofuran and piperdine were removed under vacuum to give 4.11 as a white solid. This
product was brought forward without purification.

2-((E)-2-((E)-3-(2-((E)-3,3-Dimethyl-5-sulfo-1-(4-sulfobutyl)indolin-2-ylidene)ethylidene)-2-(4(3-oxo-3-((8-oxo-8-((5-sulfamoyl-1,3,4-thiadiazol-2yl)amino)octyl)amino)propyl)phenoxy)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4-sulfobutyl)3H-indol-1-ium-5-sulfonate, 4.13
To a solution of 8-amino-N-(5-sulfamoyl-1,3,4-thiadiazol-2-yl)octanamide (4.11, 5 mg,
0.016 mmol), HATU (15 mg, 0.04 mmol), and DIPEA (0.014 mL, 0.078 mmol) in DMSO (2 mL)
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was

added

2-((E)-2-((E)-2-(4-(2-carboxyethyl)phenoxy)-3-(2-((E)-3,3-dimethyl-5-sulfo-1-(4-

sulfobutyl)indolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3,3-dimethyl-1-(4sulfobutyl)-3H-indol-1-ium-5-sulfonate (4.12, 17.9 mg, 0.018 mmol) under argon and stirred for
1 hour at room temperature. It then was purified by reverse-phase HPLC without workup [A = 2
mM ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to 100 % B in 30
min]

to

yield

2-(6-hydroxy-3-oxo-3H-xanthen-9-yl)-5-(3-(8-oxo-8-((5-sulfamoyl-1,3,4-

thiadiazol-2-yl)amino) octyl)thioureido)benzoic acid as a green solid. LRMS-LC/MS (m/z): 1320
[M + H]+.

4.3.1.3 Synthesis of a FBSA-NIR Conjugate

(3-(2-(2-(3-((2-(Cyclooctylamino)-3,5,6-trifluoro-4-sulfamoylphenyl)
sulfonyl)propanamido)ethoxy)ethoxy)propanoyl)tyrosine, 4.14
Compound 4.14 was synthesized by the following solid phase methodology. FmocTyr(tBu)-2-chlorotrityl resin (100 mg, 1.7 mmol/g) was swelled with 3 mL of DCM followed by
3 mL of DMF. A solution of 1-(9H-fluoren-9-yl)-3-oxo-2,7,10-trioxa-4-azatridecan-13-oic acid
(136 mg, 0.34 mmol), HATU (162 mg, 0.43 mmol) and DIPEA (0.09 mL, 0.51 mmol) in DMF (3
mL) was added. The reaction mixture was bubbled with argon for 2 h, and resin was washed three
times with 3 mL of DMF and 3 times with 3 mL DCM. The Fmoc protection group was removed
with a piperidine solution (20% in DMF, 3 x 5 mL) and the resin was washed three times with 3
mL of DMF and 3 times with 3 mL IPA. A solution of 3-((2-(cyclooctylamino)-3,5,6-trifluoro-4-
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sulfamoylphenyl)sulfonyl)propanoic acid (179 mg, 0.425 mmol), HATU (162 mg, 0.43 mmol)
and DIPEA (0.09 mL, 0.51 mmol) in DMF was added. Argon was bubbled for 2 h, and resin was
washed with DMF (3 x 3 mL) and DCM (3 x 3 mL). Compound 4.14 was cleaved from the resin
using a TFA:TIPS:H2O:EDT cocktail (95:2.5:2.5:2.5) and concentrated under vacuum. The
concentrated product was precipitated in diethyl ether and dried under vacuum and brought
forward without purification.

2-((E)-2-((E)-2-(4-(2-Carboxy-16-((2-(cyclooctylamino)-3,5,6-trifluoro-4sulfamoylphenyl)sulfonyl)-4,14-dioxo-7,10-dioxa-3,13-diazahexadecyl)phenoxy)-3-(2-((E)-3,3dimethyl-5-sulfo-1-(4-sulfobutyl)indolin-2-ylidene)ethylidene)cyclohex-1-en-1-yl)vinyl)-3,3dimethyl-1-(4-sulfobutyl)-3H-indol-1-ium-5-sulfonate, 4.16
To a round bottom flask was added 4.14 (4.4 mg, 0.0055) and KOH (62 mg, 0.011) in
DMSO (3 mL). This was allowed to stir for 15 min and then 4.15 was added. The reaction was
allowed to stir for 1 hr at room temperature before purification with reverse-phase HPLC without
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workup [A = 2 mM ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to
50 % B in 30 min] to 4.16 as a green solid. LRMS-LC/MS (m/z): 1646 [M+H]+.

4.3.2 Cell Lines and Cell Culture
Cell lines were purchased from American Type Culture Collection (ATCC) and cultured
as monolayers in 1640 RPMI supplemented with 10% heat-inactivated fetal bovine serum, and 1%
of penicillin-streptomycin at 37 °C in a 5% CO2:95% O2 humidified atmosphere.

4.3.3 Animal Models
Five-week-old male nu/nu mice were inoculated subcutaneously with HT-29, SKRC52, or A549
cells (5.0 × 106/mouse) on their shoulders. Growth of the tumors was measured in two
perpendicular directions every 2 days using a caliper (body weights were monitored on the same
schedule), and the volumes of the tumors were calculated as 0.5 × L × W2 (L = longest axis and W
= axis perpendicular to L in millimeters). Once tumors reached between 400 and 500 mm3 in
volume, animals were administered the dye (10 nmol) in saline (100 μL) via tail vein injection
presence or absence of 100-fold excess CAIX inhibitor acetazolamide. At various times, animals
were sacrificed by CO2 asphyxiation. Mice were imaged post-injection using a Caliper IVIS
Lumina II Imaging station coupled to an ISOON5160 Andor Nikon camera equipped with Living
Image Software Version 4.0. Image acquisition settings were as follows: lamp level, high;
excitation, 745 nM; emission, ICG; epi illumination; binning (M) 4; FOV, 12.5; f-stop, 4;
acquisition time, 1 s.
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4.4

Results and Discussion

4.4.1 In Silico Design of an Optimized Acetazolamide
The in silico design of improved acetazolamide targeting molecules was performed with
the Schrödinger product suite using a X-ray crystal structure of CAIX at 1.95 Å resolution (PDB
Code: 5FL6).9 The CAIX protein structure was prepared using the Protein Preparation Wizard and
compounds were docked using the extra precision method. Figure 4.2 shows some of the molecules
that were docked into this model. Because the large hydrophobic binding pocket of CAIX is not
occupied by the small structure of AZM, the primary design goal was to incorporate a hydrophobic
moiety to fill this pocket. It was hypothesized that the incorporation of a bulky functionality would
not only confer additional binding affinity through hydrophobic interactions with the CAIX
receptor, but also could grant additional specificity against other carbonic anhydrases.
The output of the in silico docking studies yielded a tryptophan-modified acetazolamide
(AZM-Trp) molecule that binds with a docking score of -10.008, which is significantly better than
that of the AZM molecule itself (-6.641). Docking poses of acetazolamide (left) and optimized
acetazolamide (right) are shown in Figure 4.3. The additional interactions that result in increased
binding affinity and interactions are demonstrated including new hydrophobic interactions with
HIS94 (green arrows) and new hydrogen bonds with GLN71, PRO202, and THR200 (purple
arrows).
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Figure 4.1 Chemical Structure of Acetazolamide and Binding Interactions in the Active Site of
CAIX

Figure 4.2 Selected Results of an In Silico Docking Study of AZM Derivatives
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Figure 4.3 CAIX Binding Interactions of AZM vs. AZM-Trp

4.4.2 Synthesis of AZM, AZM-Trp, and FBSA NIR Dyes
Excited by the possibility that such a small and easy modification to acetazolamide might
yield better performance, a series of molecules was synthesized in preparation for biological
evaluation. In particular, AZM-NIR, AZM-Trp-NIR, and FBSA-NIR were all synthesized,
purified, and characterized. As shown in Scheme 4.1, the acetazolamide molecule was not readily
available as the deprotected amine. However, the actual marketed version of acetazolamide was
affordable ($1/g) and the deprotection of the acyl group on the amine was readily hydrolyzed in
strong acid. Following the deprotection and recrystallization, the Trp-modified AZM was
synthesized using standard solution-phase organic synthesis techniques. The Boc-protected indole
on the Trp was used out of concern that the secondary amine might cross react with the amide
bond formation reactions. However, that was later proven to not be necessary because the
secondary amine (particularly one with aromaticity) is far less reactive than a primary amine.
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Scheme 4.1 Synthesis of Acetazolamide-Tryptophan Starting Material

The synthesis of the AZM-Trp-based near infrared (NIR) dye was undertaken as shown in
Scheme 4.2. The NIR dye 4.9 was synthesized using an amide bond formation strategy and the
Boc protecting group was removed using TFA in water (1:20). These conditions were used
primarily due to the high water solubility of the NIR conjugate. Alternative conditions would have
likely worked as well (TFA:DCM) but were not attempted. The synthesis of the AZM-NIR
conjugate 4.13 was also performed in a similar fashion as shown in Scheme 4.3.
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Scheme 4.2 Synthesis of an Acetazolamide-Tryptophan Near-Infrared Imaging Conjugate
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Scheme 4.3 Synthesis of an AZM-NIR Conjugate
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Scheme 4.4 Synthesis of a FBSA-NIR Conjugate
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4.4.3 Biological Evaluation of AZM-Trp

4.4.3.1 In Vivo Competition Binding Experiment with AZM-Trp-NIR
The first biological evaluation of the AZM-Trp was undertaken to investigate whether the
AZM-Trp-NIR dye (compound 4.9) is targeting the same receptor as acetazolamide. The manner
chosen to investigate this was to perform a competition binding experiment in mice bearing CAIXpositive xenografts. Although competition binding experiments are usually performed using an
unlabeled version of the targeting ligand, the purpose of this experiment was to determine whether
AZM-Trp was interacting with the same receptor as AZM. For this reason, AZM (4.2) and not
AZM-Trp (4.6) was used in 100-fold excess in conjugation with 4.9 for the competition control
mouse.
The in vivo imaging and biodistribution of AZM-Trp-NIR (4.9) and the competition group
was performed in mouse xenograft models using SKRC52 cells. Figure 4.4 shows the results of
the whole-body fluorescence imaging five hours after injection. In particular, the top figure shows
the bright florescence on the tumor of the left mouse and the absence of fluorescence shows tumorspecific uptake. Upon removing the tissues for the necropsy, images of the organs acquired at the
reveal the tumor-specific uptake at the tumor site in the non-competition mouse. Most importantly,
this experiment demonstrates that the AZM-Trp is targeting the same receptor as AZM because all
of the available receptors in the tumor cells of the competition control mice are occupied by the
100-fold excess of the AZM competition molecule, leaving no available receptors for the AZMTrp to bind.
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Figure 4.4 AZM-Trp-NIR Exhibits Specificity In In Vivo Competition Binding Experiment with
AZM in SKRC52 Xenografts

The next set of experiments was designed to explore whether the AZM-Trp-NIR dye would
also target additional xenografts derived from human cancer cell lines that express CAIX. Figures
4.5 and 4.6 show the whole-body NIR imaging results in HT29 tumors (images acquired 3 hours
post injection) and A549 (images acquired 5.5 hours post injection). Both of these experiments
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show that the NIR conjugate is targeted exclusively to the tumors at both of the tested time points.
This is important because it demonstrates the versatility of the AZM-Trp-NIR dye to target all
three of the CAIX positive cell lines used in Chapters 1-3.
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Figure 4.5 AZM-Trp-NIR Exhibits
Tumor-Specific Uptake in HT29 Xenografts
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Figure 4.6 AZM-Trp-NIR Exhibits Tumor-Specific Uptake in A549 Xenografts
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4.4.3.2 In Vivo Comparison of AZM-Trp-NIR vs. AZM-NIR
After successfully demonstrating that AZM-Trp-NIR has specificity and tumor uptake in
several cell lines, the next step was to prove whether the AZM-Trp can outperform the established
AZM dye. As shown in Figure 4.7, the HT29 tumor treated with AZM-Trp-NIR is much brighter
than the tumor treated with AZM-NIR. Upon necropsy, the organs also showed an increased
brightness in the tumor of the AZM-Trp-NIR mouse. Figure 4.8 also showed similar results in a
dual tumor model of MDA-MB-231 and HT29 xenografts. These data show that the Trp
modification of the AZM molecule improves the performance of AZM-based NIR dyes for in vivo
applications.
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Figure 4.7 Comparison of AZM-Trp-NIR and AZM-NIR in a HT29 Xenograft Model
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Figure 4.8 Comparison of AZM-Trp-NIR and AZM-NIR in a Dual Tumor Model of MDA-MB231 and HT29 Xenografts
S
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4.4.1 Comparison of the In Vivo Performance of Acetazolamide and FBSA Near-infrared
Conjugates
Since the AZM and FBSA projects were occurring concurrently, the final experiment was
to perform an in vivo evaluation of all three of the CAIX-NIR conjugates. This was performed
using A549 tumors in mice that were injected concurrently and images were also acquired at the
same time to provide the best measure of comparison. As can be clearly observed in Figure 4.9,
the FBSA-NIR dye is the brightest, followed by the AZM-Trp, and the unmodified AZM was the
least bright. These results were also shown in the necropsy data.
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Figure 4.9 In Vivo Comparison of Acetazolamide and FBSA NIR Conjugates
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4.5

Conclusion
The purpose of this project was to design an improved version of AZM that would

outperform AZM as a CAIX SMDC targeting ligand. AZM is a popular FDA approved drug that
has been widely used as a targeting moiety for CAIX positive cancers. However, because of its
limited potency (25 nM) and lack of specificity, it was hypothesized that it would be possible add
additional chemical functionalities to improve the specificity and potency of AZM.
After performing an in silico screening using principles of structure-based design, the Trp
modification was selected because of its improved docking scores. After performing the chemical
synthesis of the molecules, a series of in vivo experiments were performed using the NIR dyes.
First, it was necessary to show whether the AZM-Trp was actually going to the same cell-surface
receptor as that of the parental AZM molecule. To test that, the unmodified AZM molecule was
successfully used as a competition molecule in conjugation with the AZM-Trp-NIR dye. This
definitively showed that the AZM-Trp targets the same receptor. The second type of experiment
performed was to ensure that the AZM-Trp was also able to target other CAIX cell lines. This was
successfully shown in three CAIX-positive cell lines. The final, most definitive experiment was to
test if the AZM-Trp-NIR would outperform the AZM-NIR dye in whole-body NIR images. To
test this, mice were injected with 10 nmoles of either dye and subjected to whole-body imaging.
The results of this experiments showed that the Trp truly did improve the performance the AZM
targeted molecule. However, upon testing both AZM molecules against the FBSA, the higher
affinity of the FBSA outperformed the AZM-Trp. The FBSA was selected for further use in
therapeutic and radioimaging conjugates shown in Chapters 2 and 3.
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DESIGN, SYNTHESIS, AND BIOLOGICAL
EVALUATION OF TARGETED CELL BASED THERAPIES

5.1

Introduction
A common problem with the use of therapeutic cells (e.g., stem cells and T cells) is the

delivery and retention at the treatment location.129 This is commonly overcome by direct injections
at the wound site130, 131 or relying upon the natural homing mechanisms of the cells.132, 133 However,
there is an unmet need in medical indications where a localized injection may not be possible. For
example, the high fluid flow environments in acute and chronic kidney injuries whisks away the
cells or in osteoporosis, the surface area of the diseased bone is too large for localized injections.134136

Inspired by the disruptive emergence of targeting therapies like antibody-drug conjugates and

small molecule-drug conjugates, it was hypothesized that tethering a targeting ligand onto the
surface of therapeutic cells may assist with the targeting and retention of the cells at the treatment
area of interest.
A survey of existing cell surface modifications yielded several possibilities including aminereactive chemistries (e.g., N-hydroxysuccinimide, cyanuric acid) to modify cell surface amines
(e.g, lysines, N-termini) and periodate oxidation of terminal diols (e.g., sialic acids) using sodium
periodate.137 However, there were several concerns: 1) whether it would be possible to obtain
sufficiently high targeting ligand density on the cell surface, and 2) intellectual property concerns
regarding the novelty of employing these chemistries. Instead, it was hypothesized that an
alternative cell surface labeling technique developed by the Bertozzi group that uses metabolic
installation of biorthogonal chemical functionalities might be amenable for high-density labeling
of the cell surface. As shown in Figure 5.1, this method leverages the natural sialic acid
biosynthetic pathway to ‘feed’ cells unnatural metabolic precursors pre-modified with ketones,
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azides, or thiols.138

The cells are then cultured for one-to-five days and the biorthogonal

functionalities are expressed on sialic acid residues of glycosylated proteins.139-141

Figure 5.1 Metabolic labeling of cell surface sialic acids with biorthogonal functionality.

For this project, azides were chosen as a reaction partner to a strained cyclooctyne for
copper-free click chemistry; this project used a dibenzocyclooctyne (DBCO). Figure 2 shows the
structures of several common cyclooctynes and the scheme of the click reaction as it proceeds on
the cell-surface. This reaction is highly amenable to cell surface labeling because it avoids the use
of the copper catalyst required for standard alkyne-azide reactions which is known to be
cytotoxic.142 The sub-micromolar reaction concentrations and fast reaction kinetics drive the
reaction forward due to the inherent ring strain present in cyclooctynes (18 kcal/mol),143 and
provided the necessary justification for the selection of this reaction system to test the central
hypothesis posed in this chapter: Whether the transient surface modification of cells with targeting
moieties prior to systemic, intravenous implantation can help target the cells to a therapeutic area
of interest.
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Figure 5.2 Copper-free click chemistry used to attach ligands of interest on the cell surface.

5.2

Materials and Methods

5.2.1 Chemicals and Materials
H-Cys(Trt)-2-chlorotrityl resin and L-aspartic acid ß-tert-butyl 2-chlorotrityl resins were
obtained from Novabiochem (San Diego, CA). Amino acids were purchased from Chem-Impex
International (Chicago, IL). HATU was obtained from Genscript Inc. (Piscataway, NJ). Sulfuric
acid, methanol, DMSO, DMF, TFA, isopropyl alcohol, DIPEA, piperidine, CH2Cl2, K2CO3, and
all other chemical reagents were purchased from Sigma Aldrich (St. Louis, MO). Multi-well plates
were purchased from BD Biosciences (San Jose, CA). All other cell culture reagents, syringes, and
disposable items were purchased from VWR (Chicago, IL).
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5.2.2 Synthesis of DBCO-PEG6-D8 Conjugate

(26-Amino-23,26-dioxo-4,7,10,13,16,19-hexaoxa-22-azahexacosanoyl)
aspartylaspartylaspartylaspartylaspartylaspartylaspartylaspartic acid, 5.9
Compound 5.9 was synthesized by the following solid phase methodology: L-aspartic acid
β-tert-butyl ester 2-chlorotrityl resin (5.8, 100 mg, 0.64 mmole/g) was swollen with 3 mL of
dichloromethane (DCM) followed by 3 mL of dimethylformamide (DMF). After swelling the
resin in DMF, a solution of Fmoc-L-aspartic acid 4-tert-butyl ester (52.7 mg, 0.128 mmol), HATU
(68.4 mg, 0.18 mmol) and DIPEA (0.059 mL, 0.33 mmol) in DMF (3 mL) was added. Argon was
bubbled for 2 h, and resin was washed with DMF (3 x 3 mL) and IPA (3 x 3 mL). The Fmoc was
removed with a piperidine solution (20% in DMF, 3X 5 mL) and the resin was washed with DMF
(3 x 3 mL) and DCM (3 x 3 mL). The other aspartic acid residues, and Fmoc-N-amido-PEG₆-acid,
and dibenzocyclooctyne acid were added in the same manner as described for the first addition of
the aspartic acid using the same stoichiometry. Compound 5.2 was cleaved from the resin using a
TFA:TIPS:H2O:EDT (95:2.5:2.5:2.5) and concentrated under vacuum. The concentrated product
was precipitated in diethyl ether and dried under vacuum. Crude conjugate was purified by RPHPLC [A = 20 mM ammonium acetate buffer (pH 7.0), B = CH3CN, solvent gradient: 0% B to
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100 % B in 30 min] to yield the product as a white solid (41%). LRMS-LC/MS (m/z): 1562.0 [M
+ H]+.

5.2.3 Cell Lines and Cell Culture

5.2.3.1 Confocal Microscopy of Cells
Cells were seeded into chambered glass bottom plates and allowed to grow to confluence
over 24 h in the presence or absence of 20 μM N-acetylazidomannosamine. Growth medium was
replaced with 0.5 mL of fresh medium containing 10% fetal bovine serum albumin and with or
without 10 μM concentrations of various DBCO-biotin conjugates. The cells were washed three
times and then incubated with FITC-Streptavidin. Images were acquired using a confocal
microscopy (FV 1000, Olympus).

5.2.3.2 Isolation of Murine Adipose Derived Stem Cells
Isolation of the adipose derived stem cells from murine adipose deposits was done using
published procedures.144, 145 Briefly, the adipose tissues from the inguinal fat pad deposit was
surgically removed from a minimum of 10-week-old mice. The tissue was minced using a sharp
scalpel and digested using collagenase A (2 mg/mL in PBS, pH 7.4) at 37 ◦C for 30 min. The
solution was filtered (60 μm filter), and the cells were washed using centrifugation, plated in cell
culture plates, and cultured in standard cell culture medium (DMEM with 20% FBS).
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5.2.4 Animal Models
Female Swiss Webster mice were purchased from Envigo (Cambridgeshire, United
Kingdom) and housed in a sterile environment on a standard 12 h light-dark cycle and maintained
on normal rodent chow. The closed femur fractures were induced in mice according to published
procedures146 and were approved by the Purdue Institutional Care and Use Committee in
accordance with National Institutes of Health guidelines.

5.3

Results and Discussion

5.3.1 Design and Synthesis of Novel Cell Targeting Technologies
The design of the cell targeting was done with several considerations. First, there must be
sufficient clearance between the therapeutic cell surface and that of its target. A PEG6 was used to
allow for approximately 22 Å of space. Second, the design should allow for switching out the
targeting moiety without modifying the core cell surface modification chemistry. This would allow
additional ease of translation and would allow the development of this project as a platform
technology for many wound healing and oncological applications. Third, the compounds must be
non-toxic and stable under the physiological conditions mandated by ex vivo cell culture
techniques.
The first iteration of the bone-targeting moiety was alendronate, a well-established
bisphosphonate small molecule which has FDA approval for osteoporosis and other orthopedic
indications.147 In fact, there have been several published investigations using alendronate as a
SMDC and nanoparticle targeting agent.148, 149 After successfully synthesizing a DBCO-PEG6alendronate conjugate according to Scheme 5.1, it was observed to not be stable in aqueous
conditions in an LCMS study.
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Scheme 5.1 Synthesis of a DBCO-PEG6-Alendronate Conjugate

Poly aspartic acid was chosen as an alternative targeting moiety. It has been used as a bonetargeting moiety to deliver therapeutic cargos such as estradiol150 and a GSK3β inhibitor151 and
imaging agents for SPECT/CT152 and PET/CT153 radioimaging agents. The DBCO conjugate was
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synthesized using a solid-phase peptide strategy shown in Scheme 5.2 and the final conjugate 5.9
was not shown to exhibit any stability issues in the conditions required for cell surface labeling.

Scheme 5.2 Synthesis of a DBCO-PEG6-D8 Conjugate

5.3.2 In Vitro Evaluation of Cell-Surface Labeling
The cell labeling chemistry was investigated in two separate cell types: murine adipose
derived stem cells and human T cells. It was desirable to test the labeling in two types of cells to
ensure its durability across different cell types. T cells were chosen because of their facile isolation,
fast proliferation under ex vivo cell culture conditions, and, most importantly, because an eventual
goal of the project was to evaluate whether it would be possible to target them to tumors with small
molecule targeting ligands. The general procedure was the same for all of the cell types tested:
incubate the cells in the presence of 20 µM N-acetylazidomannosamine for about 24 hours later,
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wash the cells, and then incubate with or without 10 µM DBCO-containing compounds for 1 hour
at 10 uM. Figure 5.3 shows the general procedure used to label the cell surface with FITC dye.

Figure 5.3 Cell surface labeling with biotinylated fluorophores

The first in vitro studies were performed by labeling the cells with biotinylated
fluorophores. The confocal studies provide very useful qualitative information about the binding
kinetics, morphology, density of the labeling, and localization of the label on/in the cells. For
example, Figure 5.4 shows the confocal microscopy of murine adipose derived stem cells.
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Figure 5.4 In Vitro Confocal Fluorescence Microscopy Study of Murine Adipose Derived Stem
Cells

In particular, the azide-modified cells were first incubated with DBCO-PEG4-Biotin,
followed by labeling with Alexa Fluor 635-Streptavidin (AF635-Strep), and SYBR Green was
used to label the nucleus. The image shows the very bright labeling of the AF635-Strep on the
surface (shown in red) with very little internalization and the nucleus of the cell is shown in green.
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B

Figure 5.5 In Vitro Confocal Fluorescence Microscopy Study of Human T Cells
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Figure 5.5 shows another in vitro evaluation of the cell surface modification using confocal
fluorescence microscopy in human T cells. Panel A is a negative control for the non-specific
binding of FITC-streptavidin (the cells had no azido modification or and were not incubated with
DBCO-PEG4-Biotin but were incubated with FITC-streptavidin). Panel B is also a negative control
for the non-specific binding of streptavidin to the azide-modified cells (N3-positive T cells were
incubated with the FITC-streptavidin but not DBCO-PEG4-Biotin). Panel C is the positive control
of the azide-modified cells incubated with DBCO-PEG4-Biotin and subsequently FITCstreptavidin. The brightly-labeled membranes in Panel C repeat the results from the stem cells and
show that the cell labeling technology works for multiple cell types.
After performing the qualitative in vitro analysis, flow cytometry was used to provide a
more quantitative measure of the binding intensity and kinetics of the surface modification. For
example, Figure 5.6 shows that the negative controls (Panels A-C) all have a basal fluorescence
level of about 103 mean fluorescence units (MFI) but labeled cells (Panel D) have as strong shift
of nearly three orders of magnitude (~106).
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A

B

C

D

Figure 5.6 Flow Cytometry analysis of human T cells labeling.
Panel A: N3-negative T Cells + streptavidin-FITC; Panel B: N3 Negative T Cells + DBCO-biotin
+ streptavidin-FITC; Panel C: N3-positive T Cells + streptavidin-FITC; Panel D: N3- positive T
Cells + DBCO-Biotin+ streptavidin-FITC

The initial flow cytometry experiments established that the binding was specific to the
azide-modified cells and that the surface modification was sufficiently dense. The next experiment
was designed to measure how fast the DBCO modification would remain on the cell surface. For
clinical translation, it would be ideal to have as much time as possible after modification of the
cells to inject the patient. Additionally, after injecting the cells, it would be ideal to have the
targeting ligand remain on the surface of the cell as long as possible. Since the surface modification
is, by its very nature, transient, it is necessary to quantify the kinetics of the modification. To

117
perform this experiment, cells were metabolically labeled with azido groups and then incubated
with DBCO-biotin for one hour. The cells were then washed three times to remove any unreacted
DBCO-biotin and then plated into cell culture plates with fresh medium. At various time
increments, the cells were then labeled with FITC-streptavidin and then analyzed with flow
cytometry. Panel A of Figure 5.7 shows cells that modified with DBCO-biotin lose about half of
the modification in about 24 hours and the majority of it has been lost by 72 hours.
A separate experiment was performed to analyze the internalization rate of N3-labeled
sialic acids compared to those that have been modified with DBCO-biotin. This experiment was
performed identically to that of Panel A, except for ‘azide internalization’ group, which was
allowed not treated with DBCO-biotin until directly before labeling with FITC-streptavidin. As
can been seen in Panel B, the naked azides were internalized (or otherwise disposed of by the cells)
when compared to the much larger DBCO-biotin labeled cells.
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Figure 5.7 Flow cytometry study showing the internalization rate of DBCO-biotin labeled human
T cells

An important question was whether the manipulation, metabolic incorporation, and click
reaction on the surface of the cells would affect the long-term viability of the cells. Since the cells
were intended to be used for implanted back into the patient, any changes in viability would
detrimental to the technology. As can be seen in Figure 5.8, the viability of DBCO-biotin labeled

119
T cells was measured using a standard membrane exclusion assay with the 7AAD dye and
measurement using flow cytometry. After about 24 hours there was a slight decrease in the overall
viability of the cells. However, since the cells would be injected into the patient within
approximately an hour of labeling, this decrease in viability was not deemed to be prohibitive.
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Figure 5.8 Viability of T Cells after Click Chemistry Labeling of DBCO-Biotin
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5.3.3 In Vivo Evaluation of Targeted Cell Therapy

5.3.3.1 Stem Cell Delivery to a Fracture Wound Site
The in vivo biological evaluation of the targeted cellular therapy was conducted in a femur
fracture model. This wound healing model was selected for several reasons. First, and most
importantly, there were several established targeting ligands available (polyaspartic acid
and alendronate). This was important because the development of novel wound healing targeting
ligand is extremely difficult and would have been beyond the scope of the project. Second, the
peripheral location of the wound allows for facile detection of the localization of the cells after
systemic injection.
The primary endpoint of the following studies was to investigate whether the cells could
be directed to the fracture site. To measure this endpoint, the membranes of the cells were labeled
with 1,1'-dioctadecyl-3,3,3',3'-tetramethylindotricarbocyanine iodide (DiR) immediately prior to
injection. This commercially available dye was purchased from Thermo Fischer Scientific
(Waltham, MA) is designed to non-specifically anchor into the membranes of the cells by way of
a long hydrophobic C18 chain and is durable for the lengths of time needed for this studies (<7days).
DiR is excited at 750 nm and emits at 780 nm, allowing for the increased tissue penetration of the
near infrared range and is widely used for cell tracking studies.154-156
Several pilot studies were performed to assess the biodistribution of the adipose derived
stem cells. After isolating the cells from mice, the cells were labeled with polyaspartic acid and
DiR and 1 million cells were injected into the tail vein of mice with fracture in one femur. The
whole-body fluorescence images were acquired at various time points. As can be observed in
Figure 5.9, NIR images of the ventral surface of the mice show very high thoracic uptake of the
cells and that there was minimal specific uptake into the fractured right femur of the mice. Indeed,
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after performing the necropsy, there was no difference between the fractured femur and the nonfractured femur (Figure 5.10). Note that the orientation of the fractured femur in Figures 5.9 and
5.10 is marked by a red arrow to avoid confusion. Further studies were conducted to verify these
results and the fracture specific uptake was failed to be demonstrated with statistical significance.
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Figure 5.10 Necropsy of Mice Treated with Fracture-Targeted Adipose Derived Stem Cells

5.3.3.2 Targeted Delivery Human T Cells to Solid Tumors in a Xenograft Model
The final method to assess the in vivo efficacy of this targeting technology was performed
in a mouse xenograft model. To test the tumor targeting, KB (folate positive) xerographs were
grown in NOD SKID mice (n=3). After labeling with Folate-PEG11-DBCO (10 μM, 1 hr, 1% FBS
in PBS) and DiR dye, 7.5 million cells were injected into the tail vein and whole-body NIR
fluorescence images taken 1, 3, 6, 13, 24, 48, 72, and at 144 hours, the mice were sacrificed and
necropsies taken. Figure 5.11 shows that by 13 hours, the control mouse (“A”) showed that the
unlabeled T cells had migrated to the tumor through natural homing mechanisms. Surprisingly,
the targeted cells (“B” and “C”) did not show any tumor uptake. The necropsies also show minimal
targeting of the folate-labeled T cells to the tumor and both groups show a large amount of cells
have been trapped in the liver and lungs (mostly the former). Necropsies of untargeted (E) and
targeted (D) show that majority of T cells are located in liver and lungs, but the control tumor
shows an increase in tumor uptake.
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Figure 5.11 In Vivo Biodistribution of Folate-Targeted Human T Cells.

5.4

Conclusion
This project was designed as a platform technology to revolutionize the regenerative

medicine field by overcoming the single most important unmet need: therapeutic cells are
extremely difficult to deliver and retain at the wound site. Encouraged by some previous studies
using different mechanisms for labeling the cells (e.g., non-specific hydrophobic anchors,
enzymatic) showing that targeting therapeutic cells for systemic injection could be possible,157, 158
it was hypothesized that the metabolic labeling of the therapeutic cells with targeting ligands using
biorthogonal chemistries would allow for increased clinical translatability and efficacy.
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After successfully synthesizing, purifying, and characterizing DBCO-based conjugates for
fracture targeting (stem cells) and tumor targeting (T cells) metabolic labeling in T cells and
murine stem cells, extensive in vitro studies were undertaken to characterize the metabolic
labeling. These studies included kinetics, viability, expression levels using flow and confocal
microscopy.
Encouraged by the positive results observed in the early stages of the project (in vitro
evaluation of the hypothesis and organic synthesis of respective targeting ligand conjugates in the
in vitro studies), the targeted delivery of therapeutic cells was evaluated in two separate models:
cancer and wounding healing. However, it was here that the technology began to exhibit
incorrigible problems. First, the stem cells exhibited dose-limiting aggregations, resulting in the
premature death of the mice. This was presumably caused by pulmonary embolisms and has been
observed in human patients injected intravenously with stem cells.159 To overcome this issue, the
cells were injected with heparin, a commonly used anticoagulant, which allowed for the injection
of up to five million stem cells. Note, that the small T cells were not observed to have this problem
and were injected at a higher dosage level of 7.5 million cells. Despite overcoming the toxicity of
the intravenously injected ADCs, the majority of the cells were still trapped in the lungs due to the
pulmonary first-pass effect, well-established problem in the field.160, 161 The metabolic labeling of
the cell surface with small molecule targeting ligands was not shown to be efficacious in two
separate models of therapeutic cell targeting.
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ABSTRACT: Carbonic anhydrase IX (CAIX) is a membranespanning zinc metalloenzyme that catalyzes the reversible
consumption of CO2 and water to form H+ + HCO3−. Many
human cancers upregulate CAIX to help control the pH in
their hypoxic microenvironments. The consequent overexpression of CAIX on malignant cells and low expression
on normal tissues render CAIX a particularly attractive target
for small molecule inhibitors, antibody−drug conjugates, and
ligand-targeted drugs. In this study, CAIX-targeted ﬂuorescent reporter molecules were initially exploited to investigate CAIXspeciﬁc binding to multiple cancer cell lines, where they were shown to display potent and selective binding to CAIX positive
cells. A small molecule CAIX-targeted tubulysin B conjugate was then synthesized and examined for its ability to kill CAIXexpressing tumor cells in vitro. Potent therapeutic conjugates were subsequently tested in vivo and demonstrated to eliminate
solid human tumor xenografts in murine tumor models without exhibiting overt signs of toxicity. Because most solid tumors
contain hypoxic regions where CAIX is overexpressed, development of a method to selectively deliver drugs to these hypoxic
regions could aid in the therapy of otherwise diﬃcult to treat tumors.
KEYWORDS: drug targeting, tumor-speciﬁc receptor, carbonic anhydrase IX, tubulysin chemotherapy, small molecule drug conjugate,
ligand-targeted therapy

■

INTRODUCTION

the expression of a membrane-spanning carbonic anhydrase
(carbonic anhydrase IX) that catalyzes the reversible consumption of CO2 and water to form H+ + HCO3−. In this
reaction, the resulting bicarbonate can be transported across the
membrane, thereby preventing the drop in intracellular pH that
would have otherwise inhibited many metabolic pathways.10
Based upon these considerations, we hypothesize that delivery
of appropriate drugs selectively to hypoxic carbonic anhydrase IX
(CAIX)-expressing cancer cells can contribute to the treatment
of many solid tumors. Immunohistochemistry and gene
expression studies demonstrate that CAIX is upregulated in
most cancers of the lung, 11,12 colon, 13,14 pancreas, 15,16
breast,17,18 cervix,19,20 bladder,21,22 ovaries,23,24 brain,25,26 head
and neck,27 and kidneys.28,29 Moreover, CAIX expression in
healthy tissues is limited to low levels in the gastric mucosa of the
stomach, duodenum, and gall bladder.30,31 Because of this
upregulation in malignant tissues, strategies have been explored
to develop cancer cell-speciﬁc therapies for such diseases. The
most common therapeutic approaches have included use of antiCAIX antibodies,32 anti-CAIX antibody−drug conjugates

Rapidly growing tumors can outgrow their nascent vasculature,
resulting in the formation of hypoxic regions that rely on
anaerobic metabolism to survive.1 While such hypoxic niches
may comprise only a small portion of the total tumor volume,2,3
their importance in cancer survival and progression cannot be
overstated. Thus, as a result of the induction of hypoxia-inducible
factor 1a (HIF-1a), genes that control the epithelial to
mesenchymal transition (EMT) are stimulated, leading to the
transformation of cancer cells into migratory stem cell-like
mesenchymal cells that have been repeatedly implicated in
disease progression, metastasis, and overall poor prognosis.4 In
addition to their propensity to metastasize, cells that have
undergone EMT can become mitotically quiescent and thereby
insensitive to antimitotic drugs. EMT cells may also upregulate
other drug resistance mechanisms, including expression of
multidrug resistance pumps,5 enhanced DNA repair,6 and
dysregulated apoptotic pathways.7 As a consequence, tumors
that initially shrink in response to chemotherapy may rebound
when their drug-resistant hypoxic cells revert to a highly
proliferative state after termination of treatment.8
One of the hallmarks of tumor hypoxia is the production of
acidic metabolites such as lactic and carbonic acids that induce a
decrease in pH that in turn activates adaptive mechanisms to
mitigate these harsh conditions.9 One such mechanism involves
© XXXX American Chemical Society
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(ADCs),33 pan-carbonic anhydrase-targeted small-molecule
drug conjugates,34−36 and CAIX inhibitors.37−40 Herein, we
describe the design, synthesis, and biological evaluation of a
highly speciﬁc low molecular weight CAIX-targeted microtubule
inhibitor. We demonstrate that selective delivery of tubulysin B
hydrazide to multiple CAIX-expressing solid tumors leads to
rapid cancer cell death and tumor shrinkage.

■

mmol) and stirred for 1 h at room temperature. The crude
reaction mixture was puriﬁed RP-HPLC [A = 2 mM ammonium
acetate buﬀer (pH 7.0), B = CH3CN, solvent gradient 0% B to
100% B in 30 min, retention time = 22.1 min] to yield the
product 3 as a yellow powder (4.8 mg, 61%). LRMS−LC/MS
(m/z): [M + H]+ calcd for C51H54F3N5O17S3, 1162.3; found,
1162.2.
Synthesis of CAL-PEG2-D-R-D-Dap-D-C (4). H-Cys(Trt)-2chlorotrityl resin 1 (100 mg, 0.64 mmol/g) was swollen with
DCM (3 mL) for 20 min followed by DMF (3 mL) for 20 min.
After swelling, a solution of Fmoc-Asp(tBu)-OH (52.7 mg, 0.128
mmol), HATU (60.8 mg, 0.16 mmol), and DIPEA (0.056 mL,
0.32 mmol) in DMF (3 mL) was added. Argon was bubbled for 2
h, and resin was washed with DMF (3 × 3 mL) and i-PrOH (3 ×
3 mL). The Fmoc was removed with a piperidine solution (20%
in DMF, 3 × 5 mL), and the resin was washed with DMF (3 × 3
mL) and i-PrOH (3 × 3 mL). The same protocol was followed
for the remaining steps. Compound 4 was cleaved from the resin
using a TFA/TIPS/H2O/EDT cocktail (95:2.5:2.5:2.5) and
concentrated under vacuum. The concentrated product was
precipitated in diethyl ether and dried under vacuum. Crude
conjugate was puriﬁed by RP-HPLC [A = 2 mM ammonium
acetate buﬀer (pH 5.0), B = CH3CN, solvent gradient 0% B to
100% B in 30 min, retention time = 19.7 min] to yield the
product as a clear oil (36 mg, 43%). LRMS−LC/MS (m/z): [M
+ H]+ calcd for C48H74F3N13O21S3, 1322.43; found, 1322.38.
Synthesis of CAL-PEG2-D-R-D-Dap-D-C-tubulysin B, Compound 6. A solution of saturated sodium bicarbonate (10 mL) in
distilled water was bubbled with argon continuously for 30 min.
Compound 4 (1.2 mg, 0.0009 mmol) was dissolved in argonpurged HPLC grade water (2.0 mL), and the pH of the reaction
mixture was increased to 7 using the argon-purged sodium
bicarbonate solution. A solution of disulﬁde activated-tubulysin
B (5), supplied by Endocyte, 1.27 mg, 0.0012 mmol) in THF
(0.5 mL) was then added to the reaction mixture. The progress of
the reaction was monitored using LCMS, and after stirring for 30
min, the reaction was found to reach completion. Compound 6
was puriﬁed by RP-HPLC [A = 2 mM ammonium acetate buﬀer
(pH 7.0), B = CH3CN, solvent gradient 0% B to 100% B in 30
min, retention time = 23.4 min] to yield the requisite product.
LRMS−LC/MS (m/z): [M + H]+ calcd for C93H141F3N20O3S5,
2267.86; found, 1134.57 (half mass).
Cell Culture and Animal Husbandry. Cell lines were
purchased from American Type Culture Collection (ATCC) and
cultured as monolayers in 1640 rpmI supplemented with 10%
heat-inactivated fetal bovine serum, and 1% of penicillin−
streptomycin at 37 °C in a 5% CO2/95% humidiﬁed-air
atmosphere. Female athymic nu/nu mice were purchased from
Harlan Laboratories, housed in a sterile environment on a
standard 12 h light−dark cycle, and maintained on normal rodent
chow. All animal procedures were approved by the Purdue
Animal Care and Use Committee in accordance with National
Institutes of Health guidelines.
Fluorescent microscopy of CAL-PEG2-FITC Conjugate
(Compound 3). SKRC52 cells (105) were seeded into
chambered cover glass plates and allowed to grow to conﬂuence
over 24 h. Spent medium was replaced with 0.5 mL of fresh
medium containing 10% fetal bovine serum containing 25 nM
conjugate 3, alone or in combination with 100-fold excess CAIX
inhibitor (9). After incubation for 1 h at 37 °C, cells were rinsed
twice with 1 mL of media to remove unbound ﬂuorescence, and
0.5 mL of fresh incubation medium was added to the wells.
Images were acquired using confocal microscopy (FV 1000,

MATERIALS AND METHODS

Materials. H-Cys(Trt)-2-chlorotrityl resin and L-aspartic acid
β-tert-butyl 2-chlorotrityl resins were obtained from Novabiochem (San Diego, CA). Amino acids were purchased from
Chem-Impex International (Chicago, IL). Tubulysin B hydrazide (TubBH) was provided by Endocyte Inc. (West Lafayette,
IN). HATU was obtained from Genscript Inc. (Piscataway, NJ).
Sulfuric acid, MeOH, DMSO, DMF, TFA, IPA, DIPEA,
piperidine, DCM, K2CO3, and all other chemical reagents were
purchased from Sigma-Aldrich (St. Louis, MO). Amine-coated
24-well microtiter plates were purchased from BD Biosciences
(San Jose, CA). [3H]-Thymidine was obtained from Moravek
Biochemicals (Brea, CA). All other cell culture reagents, syringes,
and disposable items were purchased from VWR (Chicago, IL).
NMR spectra were recorded on a 500 MHz Bruker AV500HD
Spectrometer. All preparative HPLC was performed with an
Agilent 1200 Instrument with a reverse-phase XBridge OBD
preparative column (19 × 150 mm, 5 μm) manufactured by
Waters (Milford, MA) with UV detection at 254 nm. LRMS−
LC/MS was performed on an Agilent 1220 Inﬁnity LC with a
reverse-phase XBridge Shield RP18 column (3.0 × 50 mm, 3.5
μm).
Syntheses. Synthesis of CAL-PEG2‑Cys (2). The ﬂuorobenzosulfonamide (CAL) CAIX targeting ligand was synthesized
as previously described41 with the exception that 3-mercaptopropanoic acid was employed in place of 3-mercaptopropanol for
subsequent attachment to amine-terminated drugs (Scheme S1).
H-Cys(Trt)-2-chlorotrityl resin 1 (100 mg, 0.64 mmol/g) was
swollen with DCM (3 mL) for 20 min followed by DMF (3 mL)
for 20 min. After swelling, a solution of 3-[2-[2-(9H-ﬂuoren-9ylmethoxycarbonylamino)ethoxy]ethoxy]propanoic acid (51.1
mg, 0.128 mmol), HATU (60.8 mg, 0.16 mmol), and DIPEA
(0.056 mL, 0.32 mmol) in DMF (3 mL) was added. Argon was
bubbled for 2 h, and the resin was subsequently washed with
DMF (3 × 3 mL) and i-PrOH (3 × 3 mL). The Fmoc was
deprotected with piperidine (20% piperidine in DMF, 3 × 5 mL),
and the resin was washed with DMF (3 × 3 mL) and i-PrOH (3 ×
3 mL).
A solution of 3-((2-(cyclooctylamino)-3,5,6-triﬂuoro-4sulfamoylphenyl)sulfonyl)propanoic acid (9) (33.3 mg, 0.074
mmol), HATU (24.3 mg, 0.064 mmol), and DIPEA (0.034 mL,
0.192 mmol) in DMF was added. Argon was bubbled for 2 h, and
resin was washed DMF (3 × 3 mL) and i-PrOH (3 × 3 mL).
Compound 2 was cleaved from the resin using a TFA/TIPS/
H2O/EDT cocktail (95:2.5:2.5:2.5) and concentrated under
vacuum. The concentrated product was precipitated in Et2O and
dried under vacuum. Crude conjugate was puriﬁed by RP-HPLC
[A = 2 mM ammonium acetate buﬀer (pH 5.0), B = CH3CN,
solvent gradient 0% B to 100% B in 30 min, retention time = 18.8
min] to yield the product as a clear oil (18.5 mg, 34%). LRMS−
LC/MS (m/z): [M + H]+ calcd for C27H41F3N4O10S3, 735.2;
found, 735.2.
Synthesis of CAL-PEG2‑FITC (3). To a solution of 2 (5 mg,
0.0068 mmol) in DMF (1 mL) was added ﬂuorescein-5maleimide (3.2 mg, 0.0075 mmol) and DIPEA (0.006 mL, 0.034
B
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Olympus; 60× objective, NA: 1.42) and analyzed with Olympus
Fluoview software (Ver. 4.2).
General Procedure for Determination of Binding
Aﬃnity of CAIX-FITC Conjugates. Untransfected cells
(SKRC52, HT29, A549) or HEK293 cells transfected with
CAIX (0.25 × 106) were placed into 1.5 mL centrifuge tubes with
0.3 mL of fresh DMEM or RPMI medium containing increasing
concentrations of CAL-FITC conjugates in the presence or
absence of 100-fold excess CAL inhibitor (Scheme S1,
compound 9). All concentrations were examined in duplicate
or triplicate. After incubating for 1 h at 25 °C, cells were rinsed
twice with 1 mL of medium. The cells were transferred into a 96well plate, and the mean ﬂorescence intensity (MFI) was read by
ﬂow cytometry (BD Accuri C6, BD Biosciences). Apparent KD
was calculated by plotting mean ﬂuorescence intensity versus
concentration of FITC conjugates using GraphPad Prism 4. For
hypoxia experiments, cells were incubated under an atmosphere
containing 1% oxygen, 5% carbon dioxide, and 94% nitrogen for
24−48 h in a sealed chamber.
In Vitro Cytotoxicity Determination by 3H-Thymidine
Uptake Assay. Cells were seeded on amine-coated, 24-well
plates (BD Purecoat Amine, BD Biosciences) and allowed to
form monolayers. The spent medium in each well was replaced
with fresh medium (0.5 mL) containing various concentrations
of compound 6. After incubating for 2 h at 37 °C, cells were
rinsed 3× with fresh medium and then incubated an additional 66
h at 37 °C in fresh medium. Spent medium in each well was again
replaced with fresh medium (0.5 mL) containing 3H-thymidine
(1 μCi/mL), and the cells were incubated for an additional 4 h to
allow for [3H]-thymidine incorporation. The cells were then
washed with media (3 × 0.5 mL), treated with 5% trichloroacetic
acid (0.5 mL) for 10 min at room temperature, and dissolved in
0.25 N NaOH (0.5 mL), and 0.45 mL was transferred to
individual scintillation vials containing Ecolume scintillation
cocktail (3.0 mL). After thoroughly mixing to form a
homogeneous liquid, the vials were counted in a liquid
scintillation analyzer. The IC50 values were derived from a plot
of the percent 3H-thymidine incorporation versus log concentration using Graph Pad Prism 4.
Evaluation of in Vivo Eﬃcacy of Tubulysin Conjugates
in Tumor Xenografts. HT29 or A540 cells (2 × 106) were
injected subcutaneously into 5−6 week old female nu/nu mice.
Tumors were measured in two perpendicular directions 3×
weekly with vernier calipers, and tumor volume was calculated as
0.5 × L × W2, where L is the longest axis (in millimeters) and W
is the axis perpendicular to L (in millimeters). Dosing of CALTubB compounds was initiated when the subcutaneous tumors
reached 100−275 mm3 in volume. Dosing solutions were
prepared in saline, adjusted to 100 μL total injection volume per
mouse, and ﬁltered through a 0.22 μm ﬁlter. Solutions were
administered via tail vein injection.

Scheme 1. Synthesis of CAL-PEG2-FITC (3)

a

a

Reagents and conditions: (a) Fmoc-N-amido-PEG2-acid, HATU,
DIPEA, DMF, 2 h; (b) 20% piperidine/DMF, rt, 3 × 10 min; (c)
CAL-COOH, HATU, DIPEA, DMF, 2 h; (d) TFA/TIPS/H2O/EDT
(95:2.5:2.5:2.5), 3 × 10 min; (e) ﬂuorescein-5-maleimide, DIPEA,
DMF, rt, 2 h.

synthesized to facilitate attachment of the ligand to a ﬂexible
linker.
To determine the length of the ﬂexible linker that might best
enable the CAIX ligand to reach the bottom of its binding pocket,
the depth of the binding pocket in CAIX was estimated using its
crystal structure CAIX (PDB code: 4Q07). Analysis showed that
a linker of about 20 Å would be required for optimal docking. To
conﬁrm this assessment, several CAL-FITC conjugates with
spacers of diﬀerent lengths were synthesized and tested for their
binding aﬃnities. As shown in Figure S1, a minimal linker length
of 20 Å was required to achieve maximal binding aﬃnity; i.e., in
good agreement with the crystal structure analysis.
In Vitro Binding to CAIX-Expressing Cells. To obtain an
initial indication of which human cancer cell lines might
upregulate CAIX, we incubated SKRC-52 (human renal cell
carcinoma), HT29 (human colon adenocarcinoma), and A549
(human lung carcinoma) cells, as well as HEK293 (human
embryonic kidney) cells that were transfected with CAIX
(positive control), with 25 nM of the FITC-labeled compound
3, and then examined the cells by confocal microscopy. As shown
in the representative data of Figure 1, compound 3 labeled the
plasma membranes of SKRC-52 cells brightly (panel A) in a
manner that was readily competed by the addition of 100-fold
excess of unlabeled CAIX targeting ligand (panel B).
Importantly, similar data were also found for HT-29, A549,
and transfected HEK293 cells. These results demonstrate that all
four of the examined cell lines express CAIX receptors that can
bind compound 3. Expression of CAIX on each of the above cell
lines was further conﬁrmed by staining with an anti-CAIX
speciﬁc antibody (data not shown).
To obtain a more accurate assessment of the binding aﬃnity of
compound 3 for the aforementioned cell lines, cells were
incubated with increasing concentrations of compound 3 and
analyzed for mean ﬂuorescence intensity (MFI) by ﬂow
cytometry. As shown in Figure 1, analysis of MFI yields a
binding aﬃnity of ∼5 nM for both HT-29 and A549 cells (which

■

RESULTS
Design and Synthesis of a CAIX-Targeted Drug
Conjugate. After reviewing the properties of multiple carbonic
anhydrase inhibitors described in the literature, the inhibitor
shown in Scheme 1 was selected for further analysis based on its
aﬃnity and selectivity for CAIX. This inhibitor, developed by
Dudutiene and co-workers,41 exhibited the highest aﬃnity (50
pM) and speciﬁcity (66-fold over the closely related CAXII) of
all carbonic anhydrase inhibitors we examined. As shown in
Scheme S1, a modiﬁed version of this inhibitor, containing a
carboxylic acid instead of a hydroxyl on the sulfone, was
C
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attachment of ﬂuorescein to CAL has only a minor eﬀect on its
aﬃnity for CAIX. The fact that MFI was reduced to near
background levels upon the addition of excess unlabeled CAL
further establishes that virtually all of compound 3’s binding is
CAIX speciﬁc. These data therefore argue that a CAL-linked drug
can be targeted to CAIX-expressing cancer cells with high aﬃnity
and speciﬁcity.
Evaluation of the in Vivo Eﬃcacy of Compound 6 in
CAIX-Positive Cells. Motivated by a need for a chemotherapeutic agent that could target hypoxic regions in solid
tumors, we next used CAL to construct a therapeutic drug
conjugate compriseing CAL linked to the highly potent
chemotherapeutic agent, tubulysin B, via a ﬂexible, selfimmolative linker (Scheme 2). However, because the initial
conjugate constructed with the PEG-based linker employed in
compound 3 was found to be too insoluble for in vivo applications
(Scheme S4), the linker was redesigned to render the ﬁnal
tubulysin conjugate more water-soluble by adding several
hydrophilic amino acids. A self-immolative linker was also
inserted (Scheme 2) between the linker and the therapeutic
payload to facilitate release of unmodiﬁed tubulysin B hydrazide
upon internalization of the conjugate into the strongly reducing
environment of intracellular endosomes.42 The in vitro potency
and speciﬁcity of the ﬁnal product (compound 6) was then
evaluated in the stably transfected HEK293 cells using a 3Hthymidine incorporation assay. As shown in Figure 2A,
compound 6 successfully killed these CAIX-transfected cells
with an IC50 of 1.05 ± 0.01 nM.
In vivo eﬃcacy of compound 6 was then evaluated in athymic
nude mice bearing 200 mm3 HT29 tumor xenografts after
determining its maximum tolerated dose (MTD) by treating
mice TIW with increasing concentrations of conjugate (Figures
S5−S6). Based on an estimated MTD of 2.0 μmol/kg, all
subsequent live mouse studies were performed by intravenous
injection of 1.25 μmol/kg TIW. As shown in Figure 2B, the
aforementioned treatment regimen caused dramatic tumor
shrinkage when no competing ligand was added. However,
upon coinjection of 100-fold excess CAL containing no TubB
(compound 16, Scheme S5; competing ligand), tumor growth
increased to the rate seen in untreated controls. These data
demonstrate that treatment of HT29 tumors was CAIX-speciﬁc
and that little or no cancer cell death derived from nonspeciﬁc
extracellular release of nontargeted drug. This lack of signiﬁcant
premature drug release was further conﬁrmed by demonstrating
that conjugate-treated animals show no weight loss; i.e., an
outcome that would not have been expected if the highly toxic
free tubulysin were released systemically during transit to the
tumor. Importantly, an analogous but smaller study was
conducted using A549 mouse xenografts to ensure that the
targeted eﬃcacy was not cell-type-speciﬁc and that similar
eﬃcacy was observed (Figures S7−S8).

Figure 1. Binding of CAL-FITC (3) to SKRC-52 renal cell carcinoma
cells. Twenty-ﬁve nanomolar CAL-PEG2-FITC was incubated with
SKRC-52 cells for 1 h at 37 °C under normoxic conditions in the
absence (A) or presence (B) of excess CAL to block available ligand
binding sites. After washing, cells were analyzed for ﬂuorescein
ﬂuorescence by confocal microscopy. (C,D) Analysis of the binding
aﬃnity of CAIX-FITC (conjugate 3) for A549 (lung carcinoma) (C)
and HT29 (colorectal adenocarcinoma) (D) cells in the absence
(triangles) and presence (circles) of 100-fold excess unconjugated
inhibitor. Please note that data from diﬀerent cell lines were shown in
diﬀerent panels to demonstrate the ability of CAL to target attached
molecules to a diversity of cell lines.

■

DISCUSSION

Because of its upregulation in many cancers, carbonic anhydrase
IX has attracted increasing interest as a possible target for ligandtargeted therapeutic interventions in solid tumors. For example,
Cazzamalli et al.43 and Krall et al.44 have used the FDA-approved
small molecule CAIX inhibitor, acetazolamide (KI ≈ 25 nM), as a
targeting ligand to deliver cytotoxic compounds including
monomethyl auristatin E (MMAE), PNU-159682, maytansine,
and duocarmycin. Similarly, Lv et al., exploiting a tubulysin
conjugate of a diﬀerent small molecule inhibitor (KI ≈ 7.8 nM),
reported only stable disease when dosed TIW at 2 μmol/kg for 3

was similar to the KD for SKRC-52 and HEK293 cells that have
stability with CAIX shown in Figures S2−S4), suggesting that
D
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Scheme 2. Solid Phase Peptide Synthesis of CAL-PEG22-D-R-D-Dap-D-C-Tubulysin B (6)a

Reagents and conditions: (a) Fmoc-Asp(OtBu)-OH, HATU, DIPEA, DMF, 2 h; (b) 20% piperidine/DMF, rt, 3 × 10 min; (c) Fmoc-Dap(Boc)OH, HATU, DIPEA, DMF, 2 h; (d) 20% piperidine/DMF, rt, 3 × 10 min; (e) Fmoc-Asp(OtBu)-OH, HATU, DIPEA, DMF, 2 h; (f) 20%
piperidine/DMF, rt, 3 × 10 min; (g) Fmoc-Arg(Pbf)-OH, HATU, DIPEA, DMF, 2 h; (h) 20% piperidine/DMF, rt, 3 × 10 min; (i) N-amido-PEG2acid, HATU, DIPEA, DMF, 2 h; (j) 20% piperidine/DMF, rt, 3 × 10 min; (k) CAL-COOH, HATU, DIPEA, DMF, 2 h; (l) TFA/TIPS/H2O/EDT
(95:2.5:2.5:2.5), 3 × 15 min; (m) 5, NaHCO3, THF/H20 (1:1), rt, 30 min.
a

weeks.45 Because oﬀ-tumor toxicity commonly limits the amount
of drug that can be administered, we reasoned that use of a much
higher aﬃnity targeting ligand for delivery of our cytotoxic
payload might allow a more complete response since saturation
of tumor receptors at much lower conjugate concentrations
should reduce oﬀ-target toxicities associated with unwanted drug
release in healthy tissues. For this purpose, we scrutinized the
literature for high aﬃnity inhibitors of CAIX and found the
ﬂuoro-benzosulfonamide developed by Dudutiene and coworkers41 to bind CAIX with much higher aﬃnity and speciﬁcity.
Not surprisingly, conjugation of this inhibitor to tubulysin B
yielded better responses in tumor-bearing mice implanted with
multiple tumor types at a dose lower than was achieved with
earlier tubulysin B conjugates. While Janoniene and co-workers
previously modiﬁed a porous silicon nanosystem to display CAL
on the surface to achieve CAIX targeting, the work described in
this report is the ﬁrst use of CAL as the targeting moiety in a small
molecule drug conjugate for CAIX positive tumors.46

While most previous ligand−drug conjugates developed in our
lab have been targeted to tumor-speciﬁc receptors that readily
internalize (i.e., and thereby delivering their cargoes into
intracellular compartments), the CAL ligand used in this study
was not found to internalize. The question therefore arises
whether this inability to rapidly deliver an attached drug into the
target cell’s interior might compromise the ligand−drug
conjugate’s potency. While delivery of a ligand-targeted drug to
an endocytosing receptor is always preferred,47 we have also
previously observed that even a noninternalizing receptor can be
exploited for potent tumor-speciﬁc cytotoxicity.48 Virtually all
cell surface receptors naturally internalize during the normal
process of membrane recycling (which occurs within hours in
many cells),48,49 and even payloads that are not internalized can
be engineered for facile cell surface release if they are conjugated
to their tumor targeting ligands via a disulﬁde bond.50,51 Thus,
because many cancer cells upregulate a transplasma membrane
redox pathway that continuously generates extracellular reducing
power,52 disulﬁde bonds are much more rapidly reduced in a
E
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CAL targeting of CAIX can also be used for applications other
than the targeted delivery of tubulysin B to CAIX positive cells.
Because some of the cells that are present in hypoxic regions of
solid tumors may slowly divide, there are cytotoxic cargos other
than tubulysin B that merit further exploration, including
spliceostatins and pyrrolobenzodiazepines. Additionally, CAL
could be used to target therapeutic radionuclides to CAIX
positive cancers. Beyond the therapeutic applications, there are
also targeted imaging applications, including CAL-targeted
ﬂuorescent dyes for the ﬂuorescence-guided surgical resection
of CAIX positive tumors and CAL-targeted PET and SPECT/
CT radioimaging agents for whole body diagnosis and
monitoring of cancer.
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Figure 2. (A) In vitro cytotoxicity of compound 6 in unmodiﬁed
(triangles) and CAIX-transfected (circles) HEK293 cells. Incorporation
of 3H-thymidine was assayed in triplicate in cells treated for 2 h with
diﬀerent concentrations of compound 6. Error bars represent the
standard deviation. (B) In vivo eﬃcacy of compound 6 in nu/nu mice
bearing HT29 xenografts (n = 5 in each group). Compound 6 was
administered TIW at 1.25 μmol/kg in the presence (open circles) or
absence (triangles) of 100-fold excess CAL containing no TubB (16).
The competition and untreated groups were sacriﬁced when tumors
exceeded 1500 mm3 as per the study’s humane guidelines (day 16). (C)
Whole body masses of mice treated in panel B.
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tumor microenvironment than in the extracellular milieu of
healthy tissues.53,54 Because the targeted drugs employed in our
studies are all naturally membrane permeable, their probabilities
of entering a cancer cell over a normal cell must be very high.
Thus, assuming the average diameter of a tumor nodule to be ∼1
cm and the average diameter of a cancer cell to be ∼20 μm, a drug
released near the middle of the nodule would have to pass by
∼250 cancer cells before it could leave the tumor mass. This must
increase the probability that the cytotoxic warhead will
preferentially kill a cancer cell over a normal cell.
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